Order 2026-87-20-01 Amending the Domestic Substances List: SOR/2026-43

Canada Gazette, Part II, Volume 160, Number 6

Registration
SOR/2026-43 March 9, 2026

CANADIAN ENVIRONMENTAL PROTECTION ACT, 1999

The Minister of the Environment makes the annexed *Order 2026-87-20-01 Amending the Domestic Substances List* under subsections 66(1) [a] and 87(3) [b] and paragraphs 87(4.1)(a) [b] and (c) [b] of the *Canadian Environmental Protection Act, 1999* [c].

Ottawa, March 5, 2026

Julie Dabrusin
Minister of the Environment

Order 2026-87-20-01 Amending the Domestic Substances List

Amendments

1 Part 1 of the *Domestic Substances List* [1] is amended by deleting the following:

51-48-9

87-62-7

98-95-3

101-65-5

123-69-3

135-88-6

140-41-0

150-68-5

302-79-4

507-28-8

751-94-0

1314-20-1

1796-92-5

2944-30-1

3910-35-8

4091-99-0

4454-16-4

4995-91-9

5284-79-7

6804-07-5

7580-31-6

7717-62-6

7774-29-0

10595-60-5

14239-68-0

14816-18-3

18015-76-4

19014-53-0

19900-65-3

41284-31-5

47742-71-2

49757-42-8

50471-44-8

52236-80-3

52434-90-9

61790-11-2

61790-54-3

63148-76-5

63568-35-4

68083-40-9

68201-19-4

68228-09-1

68334-11-2

68603-64-5

68610-24-2

68648-44-2

69304-37-6

71487-01-9

73003-83-5

106068-87-5

107667-02-7

114792-68-6

132373-76-3

143106-84-7

2 (1) The heading of Part 2 of the English version of the List is replaced by the following:

CHEMICALS AND POLYMERS TO WHICH SUBSECTION 81(3) OF THE ACT APPLIES AND THAT ARE IDENTIFIED BY CHEMICAL ABSTRACTS SERVICE REGISTRY NUMBERS

(2) The List is amended by adding the following after the heading of Part 2:

DIVISION 1

Individual Substances

(3) The heading of column 2 of the table to Division 1 of Part 2 of the List is replaced by "Significant New Activities, Information To Be Provided, Period for Assessment and Classes of Persons".

(4) Division 1 of Part 2 of the List is amended by deleting "Group A" and "Group B" in column 1, the portion of column 2 opposite those Groups and the notes to each of those Groups.

(5) Division 1 of Part 2 of the List is amended by deleting the following substances in column 1 and the portion of column 2 opposite those substances:

79-07-2

107-05-1

116-66-5

117-82-8

475-71-8

603-33-8

626-39-1

944-61-6

1154-59-2

1176-74-5

1325-86-6

1326-05-2

4395-65-7

14295-43-3

38465-55-3

40615-36-9

58161-93-6

60352-98-9

64111-81-5

64325-78-6

70161-19-2

70776-86-2

83006-67-1

101200-53-7

125328-28-1

(6) Division 1 of Part 2 of the List is amended by adding the following in numerical order:

Column 1	Column 2
Substance	**Significant New Activities, Information To Be Provided, Period for Assessment and Classes of Persons**

122-60-1	1 Subsection 81(3) of the Act applies with respect to the substance oxirane, (phenoxymethyl)- in respect of (a) the use of the substance in the manufacture of any of the following products, if the product contains the substance at a concentration equal to or greater than 0.1% by weight: (i) a consumer product to which the *Canada Consumer Product Safety Act* applies, (ii) a *cosmetic* as defined in section 2 of the *Food and Drugs Act*; (b) the importation of the substance in any of the following products that contain the substance at a concentration equal to or greater than 0.1% by weight, if the total quantity imported in all such products in a calendar year is greater than 10 kg: (i) a consumer product to which the *Canada Consumer Product Safety Act* applies, (ii) a *cosmetic* as defined in section 2 of the *Food and Drugs Act*; and (c) any other activity involving the substance, if the total quantity of the substance involved across all activities, other than those referred to in paragraphs (a) and (b), in a calendar year is greater than 100 kg. 2 Despite section 1, an activity is not a significant new activity if (a) the substance is a *research and development substance* or *site-limited intermediate substance* as those terms are defined in subsection 1(1) of the *New Substances Notification Regulations (Chemicals and Polymers)*; or (b) the substance, or the product that contains the substance, is intended only for export. 3 For each proposed significant new activity, the following information must be provided to the Minister at least 90 days before the day on which the significant new activity begins: (a) for each significant new activity described in paragraph 1(a) or (b),

(i) the information specified in sections 1, 2 and 4 to 7 and paragraphs 8(d) to (f), 11(a) to (c) and 12(i) and (j) of Part 1 of Schedule 1, and

(ii) the information specified in sections 1 to 4 of Part 3 of that Schedule;

(b) for each significant new activity described in paragraph 1(c), if the total quantity of the substance that is involved in all of the activities described in that paragraph in a calendar year is greater than 100 kg but less than or equal to 1 000 kg,

(i) the information specified in sections 1 to 7 and paragraphs 11(b) and 12(a) and (g) of Part 1 of Schedule 1, and

(ii) the information specified in sections 1 to 4 of Part 3 of that Schedule;

(c) for each significant new activity described in paragraph 1(c), if the total quantity of the substance that is involved in all of the activities described in that paragraph in a calendar year is greater than 1 000 kg but less than or equal to 10 000 kg,

(i) the information specified in sections 1 to 8 and paragraphs 11(b) and 12(a) to (g) of Part 1 of Schedule 1,

(ii) the information specified in sections 56, 57 and 74 and paragraphs 75(a) and 76(a) of Part 2 of that Schedule, and

(iii) the information specified in sections 1 to 4 of Part 3 of that Schedule; and

(d) for each significant new activity described in paragraph 1(c), if the total quantity of the substance that is involved in all of the activities described in that paragraph in a calendar year is greater than 10 000 kg,

(i) the information specified in sections 1 to 8 and paragraphs 11(b) and 12(a) to (g) of Part 1 of Schedule 1,

(ii) the information specified in sections 56, 58 to 60 and 74 and paragraphs 75(a) and (b) and 76(a) to (c) of Part 2 of that Schedule, and

	(iii) the information specified in sections 1 to 4 of Part 3 of that Schedule. 4 The information provided under section 3 is to be assessed within 90 days after the day on which it is received by the Minister. 5 For the purpose of subsection 87.1(2) of the Act, persons to whom physical possession or control of the substance is transferred are not required to be notified if, at the time of the transfer, the substance is contained in a consumer product to which the *Canada Consumer Product Safety Act* applies or a *cosmetic* as defined in section 2 of the *Food and Drugs Act*.

10034-93-2	1 Subsection 81(3) of the Act applies with respect to the substance hydrazine, sulfate (1:1) in respect of (a) the use of the substance in the manufacture of any of the following products, if the product contains the substance at a concentration equal to or greater than 1.0% by weight: (i) a consumer product to which the *Canada Consumer Product Safety Act* applies, (ii) a *cosmetic* as defined in section 2 of the *Food and Drugs Act*; (b) the importation of the substance in any of the following products that contain the substance at a concentration equal to or greater than 1.0% by weight, if the total quantity imported in all such products in a calendar year is greater than 10 kg: (i) a consumer product to which the *Canada Consumer Product Safety Act* applies, (ii) a *cosmetic* as defined in section 2 of the *Food and Drugs Act*; and (c) any other activity involving the substance, if the total quantity of the substance involved across all activities, other than those referred to in paragraphs (a) and (b), in a calendar year is greater than 1 000 kg. 2 Despite section 1, an activity is not a significant new activity if (a) the substance is a *research and development substance* or *site-limited intermediate substance* as those terms are defined in subsection 1(1) of the *New Substances Notification Regulations (Chemicals and Polymers)*; or (b) the substance, or the product that contains the substance, is intended only for export. 3 For each proposed significant new activity, the following information must be provided to the Minister at least 90 days before the day on which the significant new activity begins: (a) the information specified in sections 1 to 8 and paragraphs 11(a) to (c) and 12(a) to (g) of Part 1 of Schedule 1;

	(b) the information specified in any two of sections 9, 10 and 11 of Part 2 of that Schedule; (c) the information specified in section 14, 15 or 79 of Part 2 of that Schedule; (d) the information specified in sections 56 and 74 to 76 of Part 2 of that Schedule; and (e) the information specified in sections 1 to 4 of Part 3 of that Schedule. 4 The information provided under section 3 is to be assessed within 90 days after the day on which it is received by the Minister. 5 For the purpose of subsection 87.1(2) of the Act, persons to whom physical possession or control of the substance is transferred are not required to be notified if, at the time of the transfer, the substance is contained in a consumer product to which the *Canada Consumer Product Safety Act* applies or a *cosmetic* as defined in section 2 of the *Food and Drugs Act*.

(7) Part 2 of the List is amended by adding the following after Division 1:

DIVISION 2

Groups of Substances

Significant new activity

1 (1) Subsection 81(3) of the Act applies with respect to a substance set out in the table to this subsection in respect of any activity involving the substance if the total quantity of the substance involved across all activities in a calendar year is greater than 100 kg.

Column 1 Chemical Abstracts Service Registry Number	Column 2 Substance Name
51-48-9 S'	2-Tyrosine, *O*-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-
101-65-5 S'	Carbamic acid, (methylenedi-4,1-phenylene)bis-, diphenyl ester
123-69-3 S'	Oxacycloheptadec-8-en-2-one, (*Z*)-
302-79-4 S'	Retinoic acid
507-28-8 S'	Arsonium, tetraphenyl-, chloride
751-94-0 S'	29-Nordammara-17(20),24-dien-21-oic acid, 16-(acetyloxy)-3,11-dihydroxy-, monosodium salt, (3α,4α,8α,9β,11α,13α,14β,16β,17*Z*)-
1796-92-5 S'	Benzoic acid, 5-[(3-carboxy-5-methyl-4-oxo-2,5-cyclohexadien-1-ylidene)(2,6-dichlorophenyl)methyl]-2-hydroxy-3-methyl-, disodium salt
2944-30-1 S'	9,10-Anthracenedione, 1,4-bis[(4-methoxyphenyl)amino]-
3910-35-8 S'	1*H*-Indene, 2,3-dihydro-1,1,3-trimethyl-3-phenyl-
4091-99-0 S'	Benzoic acid, 2-[3,6-bis(acetyloxy)-2,7-dichloro-9*H*-xanthen-9-yl]-
5284-79-7 S'	Cyclohexanone, 2,6-bis[(4-azidophenyl)methylene]-4-methyl-
7717-62-6 S'	Benzeneacetic acid, 1-phenyl-1,2-ethanediyl ester
7774-29-0 S'	Mercury iodide (HgI_2)
10595-60-5 S'	1,2-Ethanediamine, *N*-(1,3-dimethylbutylidene)-*N*'-[2-[(1,3-dimethylbutylidene)amino]ethyl]-
14239-68-0 S'	Cadmium, bis(diethylcarbamodithioato-*S*,*S*')-, (ß-4)-

19014-53-0 S'	9,10-Anthracenedione, 1-amino-2-[4-[(hexahydro-2-oxo-1*H*-azepin-1-yl)methyl]phenoxy]-4-hydroxy-
41284-31-5 S'	1,4-Benzenedicarboxylic acid, 2-[[4-(2,2-dicyanoethenyl)-3-methylphenyl]ethylamino]ethyl methyl ester
47742-71-2 S'	Xanthylium, 3,6-bis(diethylamino)-9-[2-(methoxycarbonyl)phenyl]-
49757-42-8 S'	Benzene, 1,1',1''-(chloromethylidyne)tris[4-methoxy-
52236-80-3 S'	Acetic acid, [4-[(1-amino-9,10-dihydro-4-hydroxy-9,10-dioxo-2-anthracenyl)oxy]phenoxy]-, ethyl ester
52434-90-9 S'	1,3,5-Triazine-2,4,6(1*H*,3*H*,5*H*)-trione, 1,3,5-tris(2,3-dibromopropyl)-
61790-11-2 S'	Fatty acids, tall-oil, zinc salts
61790-54-3 S'	Naphthenic acids, compds. with *N*-tallow alkyltrimethylenediamines
63148-76-5 S'	Benzoxazolium, 3-ethyl-5-phenyl-2-[2-[[3-(3-sulfopropyl)-2(3*H*)-benzoxazolylidene]methyl]-1-butenyl]-, hydroxide, inner salt
63568-35-4 S'	Naphthalenedisulfonic acid, diisononyl-, compd. with 1,1'-iminobis[2-propanol] (1:2)
68083-40-9 S'	Methanone, [2-hydroxy-4-[2-hydroxy-3-(octyloxy)propoxy]phenyl]phenyl-
68201-19-4 S'	Barium, acetate tallow fatty acids complexes
68228-09-1 S'	Benzoic acid, 2-[[[2,4(or 3,5)-dimethyl-3-cyclohexen-1-yl]methyl]amino]-, ethyl ester
68334-11-2 S'	Fatty acids, tall oil, compds. with 2-[(2-hydroxyphenyl)methylene]hydrazinecarboximidamide
68603-64-5 S'	Amines, *N*-(hydrogenated tallow alkyl)trimethylenedi-
68648-44-2 S'	Pyrethrins and pyrethroids, manufg.-residues

69304-37-6 S'	Disiloxane, 1,3-dichloro-1,1,3,3-tetrakis(1-methylethyl)-
71487-01-9 S'	Quaternary ammonium compounds, dicoco alkyldimethyl, nitrites
73003-83-5 S'	Arsonium, tetraphenyl-, chloride, compd. with hydrochloric acid (1:1)
106068-87-5 S'	Benzothiazolium, 5-chloro-2-[[5-[(5-chloro-1,3-diethyl-1,3-dihydro-2*H*-benzimidazol-2-ylidene)ethylidene]-3-ethyl-4-oxo-2-thiazolidinylidene]methyl]-3-ethyl-, iodide
107667-02-7 S'	Phophinodithioic acid, bis(2,4,4-trimethylpentyl)-
114792-68-6 S'	Benzene, trimethylbis(phenylmethyl)-
132373-76-3 S'	2-Naphthalenesulfonic acid, 1,5-bis(1-methylethyl)-, compd. with cyclohexanamine (1:1)
143106-84-7 S'	2-Butanone, 4-[[[1,2,3,4,4a,9,10,10a-octahydro-1,4a-dimethyl-7-(1-methylethyl)-1-phenanthrenyl]methyl](3-oxo-3-phenylpropyl)amino]-, hydrochloride, [1*R*-(1α,4aα)]-

Information to be provided

(2) For each proposed significant new activity, the following information must be provided to the Minister at least 90 days before the day on which the significant new activity begins:

(a) the information specified in sections 1, 2 and 4 to 8, paragraphs 11(b) and 12(e) and (f) and sections 14, 16 and 19 of Part 1 of Schedule 1;

(b) the information specified in section 56 and paragraphs 74(a) and (d), 75(a) and 76(a) of Part 2 of that Schedule;

(c) the results of a water solubility test of the substance and

(i) if the substance has a water solubility less than 0.1 mg/L, the information specified in section 14 of Part 2 of that Schedule,

(ii) if the substance has a water solubility equal to or greater than 0.1 mg/L and less than or equal to 1 mg/L, the information specified in sections 14 and 57 of Part 2 of that Schedule, and

(iii) if the substance has a water solubility greater than 1 mg/L, the information specified in section 57 of Part 2 of that Schedule; and

(d) the information specified in sections 1 to 4 of Part 3 of that Schedule.

Period for assessment

(3) The information provided under subsection (2) is to be assessed within 90 days after the day on which it is received by the Minister.

Significant new activity

2 (1) Subsection 81(3) of the Act applies with respect to a substance set out in the table to this subsection in respect of

(a) the use of the substance in the manufacture of any of the following products, if the product contains the substance at a concentration equal to or greater than 0.1% by weight:

(i) a consumer product to which the *Canada Consumer Product Safety Act* applies,

(ii) a *cosmetic* as defined in section 2 of the *Food and Drugs Act*;

(b) the importation of the substance in any of the following products that contain the substance at a concentration equal to or greater than 0.1% by weight, if the total quantity imported in all such products in a calendar year is greater than 10 kg:

(i) a consumer product to which the *Canada Consumer Product Safety Act* applies,

(ii) a *cosmetic* as defined in section 2 of the *Food and Drugs Act*; and

(c) any other activity involving the substance, if the total quantity of the substance involved across all activities, other than those referred to in paragraphs (a) and (b), in a calendar year is greater than 1 000 kg.

Column 1 **Chemical Abstracts Service Registry Number**	**Column 2** **Substance Name**
55-18-5 S'	Ethanamine, *N*-ethyl-*N*-nitroso-
60-35-5 S'	Acetamide
62-50-0 S'	Methanesulfonic acid, ethyl ester
62-55-5 S'	Ethanethioamide
66-27-3 S'	Methanesulfonic acid, methyl ester
79-16-3 S'	Acetamide, *N*-methyl-
87-62-7 S'	Benzenamine, 2,6-dimethyl-
96-09-3 S'	Oxirane, phenyl-
96-18-4 S'	Propane, 1,2,3-trichloro-
98-95-3 S'	Benzene, nitro-
100-63-0 S'	Hydrazine, phenyl-
106-87-6 S'	7-Oxabicyclo[4.1.0]heptane, 3-oxiranyl-

115-28-6 S'	Bicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic acid, 1,4,5,6,7,7-hexachloro-
116-14-3 S'	Ethene, tetrafluoro-
117-82-8 S'	1,2-Benzenedicarboxylic acid, bis(2-methoxyethyl) ester
123-39-7 S'	Formamide, *N*-methyl-
135-20-6 S'	Benzenamine, *N*-hydroxy-*N*-nitroso-, ammonium salt
135-88-6 S'	2-Naphthalenamine, *N*-phenyl-
140-41-0 S'	Acetic acid, trichloro-, compd. with *N*'-(4-chlorophenyl)-*N*,*N*-dimethylurea (1:1)
141-90-2 S'	4(1*H*)-Pyrimidinone, 2,3-dihydro-2-thioxo-
331-39-5 S'	2-Propenoic acid, 3-(3,4-dihydroxyphenyl)-
593-60-2 S'	Ethene, bromo-
606-20-2 S'	Benzene, 2-methyl-1,3-dinitro-
1314-20-1 S'	Thorium dioxide
1694-09-3 S'	Benzenemethanaminium, *N*-[4-[[4-(dimethylamino)phenyl][4-[ethyl[(3-sulfophenyl)methyl]amino]phenyl]methylene]-2,5-cyclohexadien-1-ylidene]-*N*-ethyl-3-sulfo-, hydroxide, inner salt, sodium salt
3296-90-0 S'	1,3-Propanediol, 2,2-bis(bromomethyl)-
4454-16-4 S'	Hexanoic acid, 2-ethyl-, nickel(2+) salt
4995-91-9 S'	Octanoic acid, nickel(2+) salt
6804-07-5 S'	Hydrazinecarboxylic acid, [(1,4-dioxido-2-quinoxalinyl)methylene]-, methyl ester
7580-31-6 S'	Hexanoic acid, 2-ethyl-, nickel salt
10046-00-1 S'	Hydroxylamine, sulfate (1:1) (salt)

13463-39-3 S'	Nickel carbonyl ($Ni(CO)_4$), (*T*-4)-
13840-56-7 S'	Boric acid (H_3BO_3), sodium salt
14816-18-3 S'	3,5-Dioxa-6-aza-4-phosphaoct-6-ene-8-nitrile, 4-ethoxy-7-phenyl-, 4-sulfide
26447-14-3 S'	Oxirane, [(methylphenoxy)methyl]-
39156-41-7 S'	1,3-Benzenediamine, 4-methoxy-, sulfate (1:1)
50471-44-8 S'	2,4-Oxazolidinedione, 3-(3,5-dichlorophenyl)-5-ethenyl-5-methyl-
64742-66-1 S'	Naphtha (petroleum), catalytic dewaxed
68610-24-2 S'	C.I. Pigment Yellow 157

Exceptions

(2) Despite subsection (1), an activity is not a significant new activity if

(a) the substance is a *research and development substance* or *site-limited intermediate substance* as those terms are defined in subsection 1(1) of the *New Substances Notification Regulations (Chemicals and Polymers)*; or

(b) the substance, or the product that contains the substance, is intended only for export.

Information to be provided

(3) For each proposed significant new activity, the following information must be provided to the Minister at least 90 days before the day on which the significant new activity begins:

(a) the information specified in sections 1, 2 and 4 to 7 and paragraphs 8(d) to (f), 11(a) to (c) and 12(i) and (j) of Part 1 of Schedule 1; and

(b) the information specified in sections 1 to 4 of Part 3 of that Schedule.

Period for assessment

(4) The information provided under subsection (3) is to be assessed within 90 days after the day on which it is received by the Minister.

Class of persons

(5) For the purpose of subsection 87.1(2) of the Act, persons to whom physical possession or control of the substance is transferred are not required to be notified if, at the time of the transfer, the substance is contained in a consumer product to which the *Canada Consumer Product Safety Act* applies or a *cosmetic* as defined in section 2 of the *Food and Drugs Act*.

Significant new activity

3 (1) Subsection 81(3) of the Act applies with respect to a substance set out in the table to this subsection in respect of

(a) the use of the substance in the manufacture of any of the following products, if the product contains the substance at a concentration equal to or greater than 1.0% by weight:

(i) a consumer product to which the *Canada Consumer Product Safety Act* applies,

(ii) a *cosmetic* as defined in section 2 of the *Food and Drugs Act*;

(b) the importation of the substance in any of the following products that contain the substance at a concentration equal to or greater than 1.0% by weight, if the total quantity imported in all such products in a calendar year is greater than 10 kg:

(i) a consumer product to which the *Canada Consumer Product Safety Act* applies,

(ii) a *cosmetic* as defined in section 2 of the *Food and Drugs Act*; and

(c) any other activity involving the substance, if the total quantity of the substance involved across all activities, other than those referred to in paragraphs (a) and (b), in a calendar year is greater than 1 000 kg.

Column 1 **Chemical Abstracts Service Registry Number**	**Column 2** **Substance Name**
59-88-1 S'	Hydrazine, phenyl-, monohydrochloride
75-25-2 S'	Methane, tribromo-
76-01-7 S'	Ethane, pentachloro-
78-88-6 S'	1-Propene, 2,3-dichloro-
79-00-5 S'	Ethane, 1,1,2-trichloro-
94-58-6 S'	1,3-Benzodioxole, 5-propyl-
107-05-1 S'	1-Propene, 3-chloro-
110-88-3 S'	1,3,5-Trioxane
123-73-9 S'	2-Butenal, (*E*)-
136-35-6 S'	1-Triazene, 1,3-diphenyl-
150-68-5 S'	Urea, *N*'-(4-chlorophenyl)-*N*,*N*-dimethyl-
591-78-6 S'	2-Hexanone
615-28-1 S'	1,2-Benzenediamine, dihydrochloride
823-40-5 S'	1,3-Benzenediamine, 2-methyl-
4170-30-3 S'	2-Butenal

18015-76-4 S'	Methanaminium, *N*-[4-[[4-(dimethylamino)phenyl]phenylmethylene]-2,5-cyclohexadien-1-ylidene]-*N*-methyl-, ethanedioate
19900-65-3 S'	Benzenamine, 4,4'-methylenebis[2-ethyl-
25376-45-8 S'	1,3-Benzenediamine, *ar*-methyl-
103122-66-3 S'	Carbamic acid, [(2-methylpropoxy)thioxomethyl]-, ethyl ester

Exceptions

(2) Despite subsection (1), an activity is not a significant new activity if

(a) the substance is a *research and development substance* or *site-limited intermediate substance* as those terms are defined in subsection 1(1) of the *New Substances Notification Regulations (Chemicals and Polymers)*; or

(b) the substance, or the product that contains the substance, is intended only for export.

Information to be provided

(3) For each proposed significant new activity, the following information must be provided to the Minister at least 90 days before the day on which the significant new activity begins:

(a) the information specified in sections 1, 2 and 4 to 7 and paragraphs 8(d) to (f), 11(a) to (c) and 12(i) and (j) of Part 1 of Schedule 1; and

(b) the information specified in sections 1 to 4 of Part 3 of that Schedule.

Period for assessment

(4) The information provided under subsection (3) is to be assessed within 90 days after the day on which it is received by the Minister.

Class of persons

(5) For the purpose of subsection 87.1(2) of the Act, persons to whom physical possession or control of the substance is transferred are not required to be notified if, at the time of the transfer, the substance is contained in a consumer product to which the *Canada Consumer Product Safety Act* applies or a *cosmetic* as defined in section 2 of the *Food and Drugs Act*.

Significant new activity

4 (1) Subsection 81(3) of the Act applies with respect to a substance set out in the table to this subsection in respect of any activity involving the substance if the total quantity of the substance involved across all activities in a calendar year is greater than 1 000 kg.

Column 1 **Chemical Abstracts Service Registry Number**	**Column 2** **Substance Name**
58-38-8 S'	10*H*-Phenothiazine, 2-chloro-10-[3-(4-methyl-1-piperazinyl)propyl]-
76-60-8 S'	Phenol, 4,4'-(3*H*-2,1-benzoxathiol-3-ylidene)bis[2,6-dibromo-3-methyl-, *S*,*S*-dioxide
77-52-1 S'	Urs-12-en-28-oic acid, 3-hydroxy-, (3β)-
93-46-9 S'	1,4-Benzenediamine, *N*,*N*'-di-2-naphthalenyl-
116-66-5 S'	1*H*-Indene, 2-3-dihydro-1,1,3,3,5-pentamethyl-4,6-dinitro-
475-71-8 S'	Benzo[*h*]benz[5,6]acridino [2,1,9,8-*klmna*]acridine-8,16-dione
603-33-8 S'	Bismuthine, triphenyl-

603-48-5 S'	Benzenamine, 4,4',4''-methylidynetris[*N*,*N*-dimethyl-
608-71-9 S'	Phenol, pentabromo-
944-61-6 S'	Benzene, 1,2,3,4-tetrachloro-5,6-dimethoxy-
1000-05-1 S'	Tetrasiloxane, 1,1,3,3,5,5,7,7-octamethyl-
1176-74-5 S'	Benzoic acid, 2-[(3,5-dibromo-4-hydroxyphenyl)(3,5-dibromo-4-oxo-2,5-cyclohexadien-1-ylidene)methyl]-, ethyl ester
1325-85-5 S'	1-Naphthalenemethanol, α,α-bis[4-(dimethylamino)phenyl]-4-(methylphenylamino)-
1325-86-6 S'	1-Naphthalenemethanol, α,α-bis[4-(diethylamino)phenyl]-4-(ethylamino)-
1326-05-2 S'	Spiro[isobenzofuran-1(3*H*),9'-[9*H*]xanthen]-3-one, 2',4',5',7'-tetrabromo-3',6'-dihydroxy-, lead salt
1326-49-4 S'	C.I. Sulphur Orange 1
2379-75-1 S'	Benzo[*b*]thiophen-3(2*H*)-one, 5-chloro-2-(5-chloro-4,7-dimethyl-3-oxobenzo[*b*]thien-2(3*H*)-ylidene)-4,7-dimethyl-
2538-84-3 S'	Anthra[9,1,2-*cde*]benzo[*rst*]pentaphene-5,10-diol, 16,17-dimethoxy-, bis(hydrogen sulfate), disodium salt
2746-81-8 S'	Heptanoic acid, 2-[4-[3-[2-(trifluoromethyl)-10*H*-phenothiazin-10-yl]propyl]-1-piperazinyl]ethyl ester
3271-22-5 S'	1,3,5-Triazine, 2,4-dimethoxy-6-(1-pyrenyl)-
4395-65-7 S'	9,10-Anthracenedione, 1-amino-4-(phenylamino)-
6257-39-2 S'	[1,1'-Biphenyl]-4-ol, 3,4',5-tris(1,1-dimethylethyl)-
6371-23-9 S'	Benzo[*b*]thiophen-3(2*H*)-one, 5,7-dichloro-2-(6-chloro-4-methyl-3-oxobenzo[*b*]thien-2(3*H*)-ylidene)-4-methyl-
6373-31-5 S'	Naphth[2,3-*c*]acridine-5,8,14(13*H*)-trione, 6,10,12-trichloro-

6408-50-0 S'	9,10-Anthracenedione, 1-(methylamino)-4-[(3-methylphenyl)amino]-
6409-68-3 S'	2-Anthracenecarboxaldehyde, 1-amino-9,10-dihydro-9,10-dioxo-, 2-[(1-amino-9,10-dihydro-9,10-dioxo-2-anthracenyl)methylene]hydrazone
6417-38-5 S'	Naphth[2,3-*c*]acridine-10-carboxamide, *N*-[5-(benzoylamino)-9,10-dihydro-9,10-dioxo-1-anthracenyl]-5,8,13,14-tetrahydro-5,8,14-trioxo-
14295-43-3 S'	Benzo[*b*]thiophen-3(2*H*)-one, 4,7-dichloro-2-(4,7-dichloro-3-oxobenzo[*b*]thien-2(3*H*)-ylidene)-
15958-61-9 S'	9,10-Anthracenedione, 1-[[4-(phenylsulfonyl)phenyl]amino]-
16834-13-2 S'	21*H*,23*H*-Porphine, 5,10,15,20-tetra-4-pyridinyl-
19163-98-5 S'	Benzoxazolium, 2-[3-[5,6-dichloro-1-ethyl-1,3-dihydro-3-(3-sulfopropyl)-2*H*-benzimidazol-2-ylidene]-1-propenyl]-3-ethyl-, hydroxide, inner salt
25857-05-0 S'	Hexanedioic acid, bis[2-[[4-(2,2-dicyanoethenyl)-3-methylphenyl]ethylamino]ethyl] ester
28118-10-7 S'	1*H*-Benzimidazolium, 5,6-dichloro-2-[3-(5,6-dichloro-1,3-diethyl-1,3-dihydro-2*H*-benzimidazol-2-ylidene)-1-propenyl]-1-ethyl-3-(3-sulfobutyl)-, hydroxide, inner salt
38465-55-3 S'	Nickel, bis[1-[4-(dimethylamino)phenyl]-2-phenyl-1,2-ethenedithiolato(2-)-*S,S*']-
40615-36-9 S'	Benzene, 1,1'-(chlorophenylmethylene)bis[4-methoxy-
42479-88-9 S'	[1,1'-Biphenyl]-4-ol, 3,4'-bis(1,1-dimethylethyl)-
52671-38-2 S'	9,10-Anthracenedione, 2,2'-[1,4-phenylenebis(1,3,4-oxadiazole-5,2-diyl)]bis[1-amino-
53184-75-1 S'	Phosphorous acid, (1-methylethylidene)di-4,1-phenylene tetrakis[(3-ethyl-3-oxetanyl)methyl] ester

54079-60-6 S'	Propanedinitrile, [[4-[[2-(2-cyclohexylphenoxy)ethyl]ethylamino]-2-methylphenyl]methylene]-
54243-60-6 S'	9,10-Anthracenedione, 1-amino-4-hydroxy-2-(4-methoxyphenoxy)-
56307-70-1 S'	Benzenediazonium, 2-methoxy-4-nitro-, salt with naphthalenedisulfonic acid (2:1)
58019-27-5 S'	Anthra[9,1,2-*cde*]benzo[*rst*]pentaphene-5,10-dione, diamino-
58161-93-6 S'	Benzoic acid, 4-[1-[[(2,4-dichlorophenyl)amino]carbonyl]-3,3-dimethyl-2-oxobutoxy]-
59583-77-6 S'	Carbamic acid, (3,4-dichlorophenyl)-, 2-[butyl[4-(2,2-dicyanoethenyl)-3-methylphenyl]amino]ethyl ester
63281-10-7 S'	3-Pyridinecarbonitrile, 5-[[2-chloro-4-(methylsulfonyl)phenyl]azo]-4-methyl-2,6-bis[[3-(2-phenoxyethoxy)propyl]amino]-
63467-19-6 S'	Propanedinitrile, [[1,2,3,4-tetrahydro-2,2,4-trimethyl-1-[2-[[(phenylamino)carbonyl]oxy]ethyl]-6-quinolinyl]methylene]-
64086-95-9 S'	9,10-Anthracenedione, 1-amino-2-bromo-4-[[4-[(1-methylethyl)amino]-6-phenyl-1,3,5-triazin-2-yl]amino]-
64086-96-0 S'	9,10-Anthracenedione, 2-acetyl-1-amino-4-[[4-[(1-methylethyl)amino]-6-phenyl-1,3,5-triazin-2-yl]amino]-
64111-81-5 S'	Phenol, 2-phenoxy-, trichloro deriv.
68910-11-2 S'	Benzenemethanol, 3,5-bis(1,1-dimethylethyl)-4-hydroxy-, reaction products with 1,3,5-trimethylbenzene
69898-66-4 S'	5-Isobenzofurancarboxylic acid, 3-[4-(diethylamino)-2-ethoxyphenyl]-3-(1-ethyl-2-methyl-1*H*-indol-3-yl)-1,3-dihydro-1-oxo-, ethyl ester

69898-67-5 S'	5-Isobenzofurancarboxylic acid, 1-[4-(diethylamino)-2-ethoxyphenyl]-1-(1-ethyl-2-methyl-1*H*-indol-3-yl)-1,3-dihydro-3-oxo-, ethyl ester
70161-19-2 S'	Benzenesulfonic acid, [(9,10-dihydro-9,10-dioxo-1,4-anthracenediyl)bis(imino-4,1-phenyleneoxy)]bis-, disodium salt
70776-86-2 S'	2-Butanone, 4-[[[1,2,3,4,4a,9,10,10a-octahydro-1,4a-dimethyl-7-(1-methylethyl)-1-phenanthrenyl]methyl](3-oxo-3-phenylpropyl)amino]-, [1*R*-(1α,4aβ,10aα)]-
72102-56-8 S'	Methylium, [4-(dimethylamino)phenyl]bis[4-(ethylamino)-3-methylphenyl]-, chloride
72102-64-8 S'	Methylium, bis[4-(dimethylamino)phenyl][4-(ethylamino)-3-methylphenyl]-, chloride
72318-87-7 S'	Phenol, [[[3-(dimethylamino)propyl]amino]methyl]-, isobutylenated
72749-91-8 S'	Benzenesulfonic acid, [(9,10-dihydro-9,10-dioxo-1,4-anthracenediyl)diimino]bis[(1,1-dimethylethyl)-, sodium salt
75908-83-7 S'	Benzenesulfonic acid, oxybis[(1,1,3,3-tetramethylbutyl)-, dipotassium salt
83006-67-1 S'	Benzenesulfonic acid, 2,2'-[(9,10-dihydro-5,8-dihydroxy-9,10-dioxo-1,4-anthracenediyl)diimino]bis[5-(1,1-dimethylethyl)-, disodium salt
83721-47-5 S'	Methanesulfonamide, 1-chloro-*N*-[2,3,4-trichloro-6-(2,4-dichlorophenoxy)phenyl]-, sodium salt
83721-48-6 S'	Methanesulfonamide, 1-chloro-*N*-[2,3,4,5-tetrachloro-6-(2,4-dichlorophenoxy)phenyl]-, sodium salt
85186-47-6 S'	Xanthylium, 9-(2-carboxyphenyl)-3,6-bis(diethylamino)-, salt with mono-C_{10-14}-alkylbenzenesulfonic acid (1:1)

86551-61-3 S'	Butanamide, 2-[2,4-bis(1,1-dimethylpropyl)phenoxy]-*N*-[4-(2-formylhydrazino)phenyl]-
90268-98-7 S'	Carbonic acid disodium salt, reaction products with aniline, 4-nitrobenzenamine, *p*-phenylenediamine, sodium sulfide, sulfur and *p*-toluidine
91696-90-1 S'	[2,6'-Bibenzothiazole]-7-sulfonic acid, 2'-(4-aminophenyl)-6-methyl-, diazotized, coupled with diazotized 4-aminobenzenesulfonic acid and resorcinol, sodium salts
93384-84-0 S'	Naphthalenesulfonic acid, reaction products with formaldehyde and hydroxybenzenesulfonic acid, ammonium salts
94248-26-7 S'	Methanesulfonamide, 1-chloro-*N*-(2-phenoxyphenyl)-, pentachloro deriv., sodium salt
104376-69-4 S'	Formaldehyde, reaction products with branched nonylphenol and xylenol, ethoxylated
108004-27-9 S'	1*H*-Imidazole-1-ethanol, α-(2,4-dichlorophenyl)-α-[2-(2,4-dichlorophenyl)cyclopropyl]-, [1α(*R**),2β]-
113163-36-3 S'	Formaldehyde, reaction products with sulfonated 1,1'-biphenyl and sulfonated terphenyl, sodium salts
117310-64-2 S'	Phosphine oxide, (butylphenyl)bis(2,6-dichlorobenzoyl)-
223777-68-2 S'	Benzenesulfonic acid, hydroxydinonyl-, branched, monoammonium salt

Information to be provided

(2) For each proposed significant new activity, the following information must be provided to the Minister at least 90 days before the day on which the significant new activity begins:

(a) the information specified in sections 1 to 8 and paragraphs 11(b) and 12(a) to (g) of Part 1 of Schedule 1;

(b) the information specified in any two of sections 9, 10 and 11 of Part 2 of that Schedule;

(c) the information specified in section 14, 15 or 79 of Part 2 of that Schedule;

(d) the information specified in sections 56 and 74 to 76 of Part 2 of that Schedule; and

(e) the information specified in sections 1 to 4 of Part 3 of that Schedule.

Period for assessment

(3) The information provided under subsection (2) is to be assessed within 90 days after the day on which it is received by the Minister.

Significant new activity

5 (1) Subsection 81(3) of the Act applies with respect to a substance set out in the table to this subsection in respect of any activity involving the substance if the total quantity of the substance involved across all activities in a calendar year is greater than 10 000 kg.

Column 1 **Chemical Abstracts Service Registry Number**	**Column 2** **Substance Name**
87-10-5 S'	Benzamide, 3,5-dibromo-*N*-(4-bromophenyl)-2-hydroxy-
96-66-2 S'	Phenol, 4,4'-thiobis[2-(1,1-dimethylethyl)-6-methyl-

132-61-6 S'	9*H*-Carbazole-3-carboxamide, *N*-(4-chlorophenyl)-2-hydroxy-
133-49-3 S'	Benzenethiol, pentachloro-
145-39-1 S'	Benzene, 1-(1,1-dimethylethyl)-3,4,5-trimethyl-2,6-dinitro-
440-17-5 S'	10*H*-Phenothiazine, 10-[3-(4-methyl-1-piperazinyl)propyl]-2-(trifluoromethyl)-, dihydrochloride
626-39-1 S'	Benzene, 1,3,5-tribromo-
1154-59-2 S'	Benzamide, 3,5-dichloro-*N*-(3,4-dichlorophenyl)-2-hydroxy-
2062-78-4 S'	2*H*-Benzimidazol-2-one, 1-[1-[4,4-bis(4-fluorophenyl)butyl]-4-piperidinyl]-1,3-dihydro-
3687-67-0 S'	3*H*-Indol-3-one, 5-bromo-2-(9-chloro-3-oxonaphtho[1,2-*b*]thien-2(3*H*)-ylidene)-1,2-dihydro-
3767-68-8 S'	9,10-Anthracenedione, 1-amino-4-(2-benzothiazolylthio)-
23077-61-4 S'	9*H*-Carbazole-1-carboxamide, *N*-(4-chlorophenyl)-2-hydroxy-
24169-02-6 S'	1*H*-Imidazole, 1-[2-[(4-chlorophenyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]-, mononitrate
27341-33-9 S'	9,10-Anthracenedione, 1-amino-4-[(methoxyphenyl)amino]-
36294-24-3 S'	Benzenepropanoic acid, 3,5-bis(1,1-dimethylethyl)-4-hydroxy-, ethyl ester
52591-25-0 S'	9,10-Anthracenedione, 2,2'-(1,3,4-oxadiazole-2,5-diyl)bis[1-amino-
60352-98-9 S'	1-Propanaminium, 3-[[4-[(2,4-dimethylphenyl)amino]-9,10-dihydro-9,10-dioxo-1-anthracenyl]amino]-*N*,*N*,*N*-trimethyl-, methyl sulfate
63467-15-2 S'	1(2*H*)-Quinolinepropanamide, 6-(2,2-dicyanoethenyl)-3,4-dihydro-2,2,4,7-tetramethyl-*N*-phenyl-
64325-78-6 S'	Adenosine, *N*-benzoyl-5'-*O*-[bis(4-methoxyphenyl)phenylmethyl]-2'-deoxy-

67219-55-0 S'	Cytidine, *N*-benzoyl-5'-*O*-[bis(4-methoxyphenyl)phenylmethyl]-2'-deoxy-
68227-79-2 S'	Benzenesulfonic acid, 2-[[9,10-dihydro-4-[(4-methylphenyl)amino]-9,10-dioxo-1-anthracenyl]amino]-5-methyl-, monoammonium salt
68938-51-2 S'	Siloxanes and silicones, 3-cyanopropyl Me, di-Me
69695-75-6 S'	9,10-Anthracenedione, 1-amino-4-[[3-[(dimethylamino)methyl]phenyl]amino]-, monohydrochloride
72812-39-6 S'	Methylium, bis(4-amino-3,5-dimethylphenyl)(2,6-dichlorophenyl)-, phosphate (1:1)
72828-93-4 S'	1-Propanaminium, 3-[[9,10-dihydro-4-[(4-methylphenyl)amino]-9,10-dioxo-1-anthracenyl]amino]-*N*,*N*,*N*-trimethyl-, methyl sulfate
73398-86-4 S'	Pyridine, 4-(3-chloro-5-propylphenyl)-
73398-87-5 S'	Pyridine, 4-(4-chloro-3-propylphenyl)-
83968-86-9 S'	9,10-Anthracenedione, 1-amino-4-[[3-[(dimethylamino)methyl]phenyl]amino]-, monoacetate
85702-64-3 S'	3*H*-Indol-3-one, 5,7-dibromo-2-(5-bromo-7-chloro-1,3-dihydro-3-oxo-2*H*-indol-2-ylidene)-1,2-dihydro-
101200-53-7 S'	Pyridine, 2-[3-(3-chlorophenyl)propyl]-
103331-97-1 S'	Fatty acids, tallow, hydrogenated, [6-[bis(methoxymethyl)amino]-1,3,5-triazine-2,4-diyl]bis[[(methoxymethyl)imino]methylene] ester
103331-98-2 S'	Fatty acids, tallow, hydrogenated, hexaesters with 2-[[[4-[[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl](hydroxymethyl)amino]-6-[(hydroxymethyl)(methoxymethyl)amino]-1,3,5-triazin-2-yl](methoxymethyl)amino]methoxy]-1,3-propanediol

125328-28-1 S'	Phenol, 4,4'-(1-methylethylidene)bis-, reaction products with hexakis(methoxymethyl)melamine

Information to be provided

(2) For each proposed significant new activity, the following information must be provided to the Minister at least 90 days before the day on which the significant new activity begins:

(a) the information specified in sections 1 to 8 and paragraphs 11(b) and 12(a) to (g) of Part 1 of Schedule 1;

(b) the information specified in any two of sections 9, 10 and 11 of Part 2 of that Schedule;

(c) the information specified in section 14, 15 or 79 of Part 2 of that Schedule;

(d) the information specified in sections 56 and 74 to 76 of Part 2 of that Schedule; and

(e) the information specified in sections 1 to 4 of Part 3 of that Schedule.

Period for assessment

(3) The information provided under subsection (2) is to be assessed within 90 days after the day on which it is received by the Minister.

Significant new activity

6 (1) Subsection 81(3) of the Act applies with respect to a substance set out in the table to this subsection in respect of any activity involving the substance if the total quantity of the substance involved across all activities in a calendar year is greater than 100 kg.

Column 1 Chemical Abstracts Service Registry Number	Column 2 Substance Name
79-07-2 S'	Acetamide, 2-chloro-
131-52-2 S'	Phenol, pentachloro-, sodium salt
15545-48-9 S'	Urea, *N*'-(3-chloro-4-methylphenyl)-*N*,*N*-dimethyl
24602-86-6 S'	Morpholine, 2,6-dimethyl-4-tridecyl-
55290-64-7 S'	1,4-Dithiin, 2,3-dihydro-5,6-dimethyl-, 1,1,4,4-tetraoxide

Information to be provided

(2) For each proposed significant new activity, the following information must be provided to the Minister at least 90 days before the day on which the significant new activity begins:

(a) the information specified in sections 1 to 7 and paragraphs 8(d) to (f), 11(b) and 12(a) to (g), (i) and (j) of Part 1 of Schedule 1; and

(b) the information specified in sections 1 to 4 of Part 3 of that Schedule.

Period for assessment

(3) The information provided under subsection (2) is to be assessed within 90 days after the day on which it is received by the Minister.

Significant new activity

7 (1) Subsection 81(3) of the Act applies with respect to a substance set out in the table to this subsection in respect of

(a) the use of the substance in the manufacture of any of the following products, if the product contains the substance at a concentration equal to or greater than 0.1% by weight:

(i) a consumer product to which the *Canada Consumer Product Safety Act* applies,

(ii) a *cosmetic* as defined in section 2 of the *Food and Drugs Act*;

(b) the importation of the substance in any of the following products that contain the substance at a concentration equal to or greater than 0.1% by weight, if the total quantity imported in all such products in a calendar year is greater than 10 kg:

(i) a consumer product to which the *Canada Consumer Product Safety Act* applies,

(ii) a *cosmetic* as defined in section 2 of the *Food and Drugs Act*; and

(c) any other activity involving the substance, if the total quantity of the substance involved across all activities, other than those referred to in paragraphs (a) and (b), in a calendar year is greater than 1 000 kg.

Column 1 **Chemical Abstracts Service Registry Number**	**Column 2** **Substance Name**
101-61-1 S'	Benzenamine, 4,4'-methylenebis[*N*,*N*-dimethyl-
131-18-0 S'	1,2-Benzenedicarboxylic acid, dipentyl ester
492-80-8 S'	Benzenamine, 4,4'-carbonimidoylbis[*N*,*N*-dimethyl-
569-61-9 S'	Benzenamine, 4-[(4-aminophenyl)(4-imino-2,5-cyclohexadien-1-ylidene)methyl]-, monohydrochloride

25321-14-6 S'	Benzene, methyldinitro-

Exceptions

(2) Despite subsection (1), an activity is not a significant new activity if

(a) the substance is a *research and development substance* or *site-limited intermediate substance* as those terms are defined in subsection 1(1) of the *New Substances Notification Regulations (Chemicals and Polymers)*; or

(b) the substance, or the product that contains the substance, is intended only for export.

Information to be provided

(3) For each proposed significant new activity, the following information must be provided to the Minister at least 90 days before the day on which the significant new activity begins:

(a) the information specified in sections 1 to 8 and paragraphs 11(a) to (c) and 12(a) to (g) of Part 1 of Schedule 1;

(b) the information specified in any two of sections 9, 10 and 11 of Part 2 of that Schedule;

(c) the information specified in section 14, 15 or 79 of Part 2 of that Schedule;

(d) the information specified in sections 56 and 74 to 76 of Part 2 of that Schedule; and

(e) the information specified in sections 1 to 4 of Part 3 of that Schedule.

Period for assessment

(4) The information provided under subsection (3) is to be assessed within 90 days after the day on which it is received by the Minister.

Class of persons

(5) For the purpose of subsection 87.1(2) of the Act, persons to whom physical possession or control of the substance is transferred are not required to be notified if, at the time of the transfer, the substance is contained in a consumer product to which the *Canada Consumer Product Safety Act* applies or a *cosmetic* as defined in section 2 of the *Food and Drugs Act*.

Significant new activity

8 (1) Subsection 81(3) of the Act applies with respect to a substance set out in the table to this subsection in respect of any activity involving the substance if the total quantity of the substance involved across all activities in a calendar year is greater than 100 kg.

Column 1 **Chemical Abstracts Service Registry Number**	**Column 2** **Substance Name**
3701-40-4 S'	2,7-Naphthalenedisulfonic acid, 4-hydroxy-3-[[4'-[(2-hydroxy-1-naphthalenyl)azo]-2,2'-dimethyl[1,1'-biphenyl]-4-yl]azo]-, disodium salt
6368-72-5 S'	2-Naphthalenamine, *N*-ethyl-1-[[4-(phenylazo)phenyl]azo]-
6420-06-0 S'	1-Naphthalenesulfonic acid, 4-hydroxy-3-[[4'-[(1-hydroxy-5-sulfo-2-naphthalenyl)azo]-3,3'-dimethyl[1,1'-biphenyl]-4-yl]azo]-, disodium salt
12789-03-6 S'	Chlordane
68400-36-2 S'	2,7-Naphthalenedisulfonic acid, 4-amino-5-hydroxy-6-[[4'-[(4-hydroxyphenyl)azo]-3,3'-dimethyl[1,1'-biphenyl]-4-yl]azo]-3-[(4-nitrophenyl)azo]-, disodium salt

68512-30-1 S'	Phenol, methylstyrenated
70210-08-1 S'	2-Naphthalenesulfonamide, *N*-[2-(acetyloxy)ethyl]-6-hydroxy-*N*-methyl-5-[[4-(phenylazo)phenyl]azo]-
128683-35-2 S'	Residues (oil sand), atm. tower

Information to be provided

(2) For each proposed significant new activity, the following information must be provided to the Minister at least 90 days before the day on which the significant new activity begins:

(a) the information specified in sections 1 to 7 and paragraphs 11(b) and 12(a) to (g), (i) and (j) of Part 1 of Schedule 1;

(b) the information specified in any two of sections 62, 63 and 64 of Part 2 of that Schedule, selected on the basis of the most significant route of potential human exposure to the substance;

(c) the information specified in sections 65 and 69 to 73 of Part 2 of that Schedule; and

(d) the information specified in sections 1 to 4 of Part 3 of that Schedule.

Period for assessment

(3) The information provided under subsection (2) is to be assessed within 90 days after the day on which it is received by the Minister.

3 (1) The heading of Part 4 of the English version of the List is replaced by the following:

CHEMICALS AND POLYMERS TO WHICH SUBSECTION 81(3) OF THE ACT APPLIES AND THAT ARE IDENTIFIED BY CONFIDENTIAL SUBSTANCE IDENTITY NUMBERS

(2) The heading of column 2 of the table to Part 4 of the List is replaced by "Significant New Activities, Information To Be Provided, Period for Assessment and Classes of Persons".

4 The heading of column 2 of the table to Part 6 of the List is replaced by "Significant New Activities, Information To Be Provided, Period for Assessment and Classes of Persons".

5 The heading of Part 8 of the English version of the List is replaced by the following:

INANIMATE BIOTECHNOLOGY PRODUCTS AND LIVING ORGANISMS TO WHICH SUBSECTION 81(3) OR 106(3) OF THE ACT APPLIES AND THAT ARE IDENTIFIED BY CONFIDENTIAL SUBSTANCE IDENTITY NUMBERS

6 The List is amended by adding, after Part 8, the Schedule 1 set out in the schedule to this Order.

Coming into Force

7 This Order comes into force on the day on which it is registered.

SCHEDULE

(Section 6)

SCHEDULE 1

(Parts 2 and 4)

Information Concerning Significant New Activities in Respect of Which a Substance is Subject to Subsection 81(3) of the Act

Definitions

1 The following definitions apply in this Schedule.

OECD
means the Organisation for Economic Co-operation and Development. (*OCDE*)

OECD Guidelines
means the OECD Guidelines for the Testing of Chemicals, published by the OECD. (*lignes directrices de l'OCDE*)

OECD principles of good laboratory practice
means the principles set out in the OECD document entitled *OECD Principles on Good Laboratory Practice*, Number 1 of the OECD Series on Principles of Good Laboratory Practice and Compliance Monitoring. (*principes relatifs aux bonnes pratiques de laboratoire de l'OCDE*)

PART 1

Information in Respect of Significant New Activities and Substances

1 A description of the significant new activity in relation to the substance.

2 The quantity of the substance that is anticipated to be used, manufactured or imported in a calendar year.

3 If known, the three sites in Canada where the greatest quantity of the substance is anticipated to be used or processed and the anticipated quantity by site.

4 The chemical name of the substance, established in accordance with the chemical nomenclature rules of the International Union of Pure and Applied Chemistry or the Chemical Abstracts Service.

5 The trade names of the substance and the synonyms of its chemical name, if known.

6 The Chemical Abstracts Service registry number of the substance, if such a number can be assigned.

7 A safety data sheet for the substance, if available.

8 The following information in respect of the substance:

(a) its molecular formula;

(b) its structural formula;

(c) its gram molecular weight;

(d) the degree of purity in its technical grade composition, if applicable;

(e) the known impurities in its technical grade composition and their concentration by weight; and

(f) any additives, stabilizers and solvents present when it is studied and their concentration by weight.

9 The composition of the substance, including the constituents — such as monomers and other reactants, additives, stabilizers and solvents — that are present when the substance is studied, as well as the Chemical Abstracts Service registry number, if such a number can be assigned, and concentration by weight of each constituent.

10 The reaction scheme for the substance.

11 The following information in respect of the product and, if known, any end-use products that contain the substance:

(a) a description of the product and end-use products, the intended use and method of application of the product and end-use products and the function of the substance in the product and end-use products;

(b) the concentration of the substance in the product and end-use products;

(c) the quantity of the product and end-use products that the person proposing the significant new activity expects to sell in Canada in a calendar year; and

(d) a statement as to whether the public is anticipated to be significantly exposed to the substance in the product or end-use products — taking into account factors including the concentration of the substance in the product or end-use products, the duration, frequency and circumstances of exposure, whether the substance is released intentionally or not from the product or end-use products during use, and factors that may limit direct human exposure — and, if the public is not anticipated to be significantly exposed, information substantiating the statement.

12 The following information in respect of exposure to the substance:

(a) the historical uses of the substance and its anticipated uses;

(b) a description of the recommended methods for destroying or disposing of the substance;

(c) a description of the expected modes of transportation and storage of the substance;

(d) the size and type of container to be used for transporting and storing the substance;

(e) an indication of the components of the environment (water, air and land) into which the substance is anticipated to be released, the quantity of the substance anticipated to be released into each of those components and, if the substance is anticipated to be released into water or land, a description of the receiving body of water or type of land;

(f) the quantity of the substance that is anticipated to be released into municipal wastewater treatment systems;

(g) any factors that may limit environmental exposure to the substance;

(h) a statement as to whether the substance is anticipated to be released into the aquatic environment in a quantity exceeding 3 kg per day, per site, averaged monthly and after wastewater treatment and, if the quantity released is anticipated to be less than or equal to 3 kg per day, per site, information substantiating the statement;

(i) a statement as to whether the substance will be used in products intended for use by or for children; and

(j) the anticipated degree of direct human exposure to the substance, including the concentration to which humans will be directly exposed, the duration and frequency of the exposure, the circumstances leading to the exposure and factors that may limit the exposure.

13 The following information in respect of the substance:

(a) its physical state; and

(b) a statement as to whether it is formulated for dispersal in water.

14 (1) A flow diagram of the overall process and the steps involved in the significant new activity that result or may result in the entry or release of the substance into the environment, including the use of holding tanks, process tanks and distillation towers, if applicable.

(2) A description of each of the steps referred to in subsection (1), the quantities and concentrations that are or may be released at each step, the physical form of the substance for each location where the substance will or may be released and, if applicable, the anticipated frequency, duration and rate of release.

15 A description of the manufacturing process, including descriptions of the reactants used to produce the substance, the points of entry of all reactants, the reaction stoichiometry, the chemical conversions, the points of release of the substance, the processes to eliminate environmental release of the substance and the nature (batch or continuous) and scale of the process.

16 A description of the waste management practices to be implemented to prevent or minimize the release of the substance at the facility, if any, where the significant new activity will be conducted and other information related to waste management, including

(a) the quantity of the substance, in effluents and emissions, that is anticipated to be released into the environment, including average and peak concentrations;

(b) if the substance is anticipated to be released into a municipal wastewater system, the name and address of the municipal wastewater treatment facility, the name of the receiving body of water and the location of the point of release, as well as the total quantity of the substance that is anticipated to be released at that location per day, expressed in kilograms;

(c) if the substance is anticipated to be released directly into surface waters, the name of the receiving body of water and the location of the point of release, as well as the total quantity of the substance that is anticipated to be released at that location per day, expressed in kilograms; and

(d) if waste containing the substance is anticipated to be treated on-site, a description of the treatment system, the total quantity of the substance that is anticipated to be released per year, expressed in kilograms, the percentage of the substance to be removed from the

waste, the name of the receiving body of water and the location of the point of release.

17 A description of the degree to which the significant new activity will result in dispersal of the substance or, if the substance will not be dispersed, a description of how it will be contained or consumed.

18 A description of the methods to be used by the person proposing the significant new activity to destroy or dispose of the substance, as well as the following information:

(a) the total quantity of the substance to be destroyed or disposed of by each method per year, expressed in kilograms;

(b) a description of the types of waste that will contain the substance, the anticipated quantity of each type of waste to be produced per year, expressed in kilograms, the classification of the waste under provincial law and the site of destruction or disposal of the waste; and

(c) a description of the methods to be used to treat and dispose of containers that have been used to transport and store the substance.

19 An estimate of the daily and annual quantities of the substance that are anticipated to be released as fugitive emissions from all steps involved in the significant new activity.

PART 2

Data and Reports from Studies in Respect of Substances

1 The data and a report from a study in respect of the substance, conducted in accordance with the methodology described in *Test No. 107: Partition Coefficient (n-octanol/water): Shake Flask Method* of the OECD Guidelines, Section 1, that is current at the time the study is conducted.

2 (1) The data and a report from a study in respect of the substance, conducted in accordance with the methodology described in *Test No. 111: Hydrolysis as a Function of pH* of the OECD Guidelines, Section 1, that is current at the time the study is conducted.

(2) The products of the hydrolysis, if known.

3 The data and a report from a study in respect of the substance, conducted in accordance with the methodology described in *Test No. 117: Partition Coefficient (n-octanol/water), HPLC Method* of the OECD Guidelines, Section 1, that is current at the time the study is conducted.

4 The data and a report from a study in respect of the substance, conducted in accordance with the methodology described in *Test No. 120: Solution/Extraction Behaviour of Polymers in Water* of the OECD Guidelines, Section 1, that is current at the time the study is conducted.

5 The data and a report from a study in respect of the substance, conducted in accordance with the methodology described in *Test No. 121: Estimation of the Adsorption Coefficient (Koc) on Soil and on Sewage Sludge using High Performance Liquid Chromatography (HPLC)* of the OECD Guidelines, Section 1, that is current at the time the study is conducted.

6 The data and a report from a study in respect of the substance, conducted in accordance with the methodology described in *Test No. 123: Partition Coefficient (1-Octanol/Water): Slow-Stirring Method* of the OECD Guidelines, Section 1, that is current at the time the study is conducted.

7 The data and a report from a study in respect of the substance, conducted in accordance with the methodology described in *Test No. 124: Determination of the Volume Specific Surface Area of Manufactured Nanomaterials* of the OECD Guidelines, Section 1, that is current at the time the study is conducted.

8 The data and a report from a study in respect of the substance, conducted in accordance with the methodology described in *Test No. 125: Nanomaterial Particle Size and Size Distribution of Nanomaterials* of the OECD Guidelines, Section 1, that is current at the time the study is conducted.

9 The data and a report from a study in respect of the substance, conducted in accordance with

(a) the methodology described in *Test No. 201: Freshwater Alga and Cyanobacteria, Growth Inhibition Test* of the OECD Guidelines, Section 2, that is current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

10 The data and a report from a study in respect of the substance, conducted in accordance with

(a) the methodology described in *Test No. 202: Daphnia sp. Acute Immobilisation Test* of the OECD Guidelines, Section 2, that is current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

11 The data and a report from a study in respect of the substance, conducted in accordance with

(a) the methodology described in *Test No. 203: Fish, Acute Toxicity Test* of the OECD Guidelines, Section 2, that is current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

12 The data and a report from a study in respect of the substance, conducted in accordance with

(a) the methodology described in *Test No. 210: Fish, Early-life Stage Toxicity Test* of the OECD Guidelines, Section 2, that is current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

13 The data and a report from a study in respect of the substance, conducted in accordance with

(a) the methodology described in *Test No. 211: Daphnia magna Reproduction Test* of the OECD Guidelines, Section 2, that is current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

14 The data and a report from a study in respect of the substance, conducted in accordance with

(a) the methodology described in *Test No. 218: Sediment-Water Chironomid Toxicity Test Using Spiked Sediment* of the OECD Guidelines, Section 2, that is current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

15 The data and a report from a study in respect of the substance, conducted in accordance with

(a) the methodology described in *Test No. 225: Sediment-Water Lumbriculus Toxicity Test Using Spiked Sediment* of the OECD Guidelines, Section 2, that is current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

16 The data and a report from a study in respect of the substance, conducted in accordance with

(a) the methodology described in *Test No. 229: Fish Short Term Reproduction Assay* of the OECD Guidelines, Section 2, that is current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

17 The data and a report from a study in respect of the substance, conducted in accordance with

(a) the methodology described in *Test No. 233: Sediment-Water Chironomid Life-Cycle Toxicity Test Using Spiked Water or Spiked Sediment* of the OECD Guidelines, Section 2, that is current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

18 The data and a report from a study in respect of the substance, conducted in accordance with

(a) the methodology described in *Test No. 234: Fish Sexual Development Test* of the OECD Guidelines, Section 2, that is current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

19 (1) The data and a report from a study in respect of the substance, conducted in accordance with

(a) the methodology described in *Test No. 301: Ready Biodegradability* of the OECD Guidelines, Section 3, that is current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

(2) The products of biodegradation, if known.

20 The data and a report from a study in respect of the substance, conducted in accordance with

(a) the methodology described in *Test No. 305: Bioaccumulation in Fish: Aqueous and Dietary Exposure* of the OECD Guidelines, Section 3, that is current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

21 The data and a report from a study in respect of the substance, conducted in accordance with

(a) the methodology described in *Test No. 402: Acute Dermal Toxicity* of the OECD Guidelines, Section 4, that is current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

22 The data and a report from a study in respect of the substance, conducted in accordance with

(a) the methodology described in *Test No. 403: Acute Inhalation Toxicity* of the OECD Guidelines, Section 4, that is current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

23 The data and a report from a study in respect of the substance, conducted in accordance with

(a) the methodology described in *Test No. 404: Acute Dermal Irritation/Corrosion* of the OECD Guidelines, Section 4, that is current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

24 The data and a report from a study in respect of the substance, conducted in accordance with

(a) the methodology described in *Test No. 406: Skin Sensitisation* of the OECD Guidelines, Section 4, that is current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

25 The data and a report from a study in respect of the substance, conducted in accordance with

(a) the methodology described in *Test No. 407: Repeated Dose 28-day Oral Toxicity Study in Rodents* of the OECD Guidelines, Section 4, that is current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

26 The data and a report from a study in respect of the substance, conducted in accordance with

(a) the methodology described in *Test No. 410: Repeated Dose Dermal Toxicity: 21/28-day Study* of the OECD Guidelines, Section 4, that is current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

27 The data and a report from a study in respect of the substance, conducted in accordance with

(a) the methodology described in *Test No. 411: Subchronic Dermal Toxicity: 90-day Study* of the OECD Guidelines, Section 4, that is current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

28 The data and a report from a study in respect of the substance, conducted in accordance with

(a) the methodology described in *Test No. 412: Subacute Inhalation Toxicity: 28-Day Study* of the OECD Guidelines, Section 4, that is current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

29 The data and a report from a study in respect of the substance, conducted in accordance with

(a) the methodology described in *Test No. 413: Subchronic Inhalation Toxicity: 90-day Study* of the OECD Guidelines, Section 4, that is current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

30 The data and a report from a study in respect of the substance, conducted in accordance with

(a) the methodology described in *Test No. 414: Prenatal Developmental Toxicity Study* of the OECD Guidelines, Section 4, that is current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

31 The data and a report from a study in respect of the substance, conducted in accordance with

(a) the methodology described in *Test No. 415: One-Generation Reproduction Toxicity Study* of the OECD Guidelines, Section 4, that is current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

32 The data and a report from a study in respect of the substance, conducted in accordance with

(a) the methodology described in *Test No. 416: Two-Generation Reproduction Toxicity* of the OECD Guidelines, Section 4, that is current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

33 The data and a report from a study in respect of the substance, conducted in accordance with

(a) the methodology described in *Test No. 417: Toxicokinetics* of the OECD Guidelines, Section 4, that is current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

34 The data and a report from a study in respect of the substance, conducted in accordance with

(a) the methodology described in *Test No. 420: Acute Oral Toxicity - Fixed Dose Procedure* of the OECD Guidelines, Section 4, that is current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

35 The data and a report from a study in respect of the substance, conducted in accordance with

(a) the methodology described in *Test No. 421: Reproduction/Developmental Toxicity Screening Test* of the OECD Guidelines, Section 4, that is current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

36 The data and a report from a study in respect of the substance, conducted in accordance with

(a) the methodology described in *Test No. 422: Combined Repeated Dose Toxicity Study with the Reproduction/Developmental Toxicity Screening Test* of the OECD Guidelines, Section 4, that is current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

37 The data and a report from a study in respect of the substance, conducted in accordance with

(a) the methodology described in *Test No. 423: Acute Oral toxicity – Acute Toxic Class Method* of the OECD Guidelines, Section 4, that is current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

38 The data and a report from a study in respect of the substance, conducted in accordance with

(a) the methodology described in *Test No. 425: Acute Oral Toxicity: Up-and-Down Procedure* of the OECD Guidelines, Section 4, that is current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

39 The data and a report from a study in respect of the substance, conducted in accordance with

(a) the methodology described in *Test No. 427: Skin Absorption: In Vivo Method* of the OECD Guidelines, Section 4, that is current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

40 The data and a report from a study in respect of the substance, conducted in accordance with

(a) the methodology described in *Test No. 428: Skin Absorption: In Vitro Method* of the OECD Guidelines, Section 4, that is current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

41 The data and a report from a study in respect of the substance, conducted in accordance with

(a) the methodology described in *Test No. 429: Skin Sensitisation: Local Lymph Node Assay* of the OECD Guidelines, Section 4, that is current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

42 The data and a report from a study in respect of the substance, conducted in accordance with

(a) the methodology described in *Test No. 430: In Vitro Skin Corrosion: Transcutaneous Electrical Resistance Test Method (TER)* of the OECD Guidelines, Section 4, that is current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

43 The data and a report from a study in respect of the substance, conducted in accordance with

(a) the methodology described in *Test No. 431: In vitro skin corrosion: reconstructed human epidermis (RHE) test method* of the OECD Guidelines, Section 4, that is current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

44 The data and a report from a study in respect of the substance, conducted in accordance with

(a) the methodology described in *Test No. 436: Acute Inhalation Toxicity – Acute Toxic Class Method* of the OECD Guidelines, Section 4, that is current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

45 The data and a report from a study in respect of the substance, conducted in accordance with

(a) the methodology described in *Test No. 439: In Vitro Skin Irritation: Reconstructed Human Epidermis Test Method* of the OECD Guidelines, Section 4, that is current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

46 The data and a report from a study in respect of the substance, conducted in accordance with

(a) the methodology described in *Test No. 451: Carcinogenicity Studies* of the OECD Guidelines, Section 4, that is current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

47 The data and a report from a study in respect of the substance, conducted in accordance with

(a) the methodology described in *Test No. 471: Bacterial Reverse Mutation Test* of the OECD Guidelines, Section 4, that is current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

48 The data and a report from a study in respect of the substance, conducted in accordance with

(a) the methodology described in *Test No. 473: In Vitro Mammalian Chromosomal Aberration Test* of the OECD Guidelines, Section 4, that is current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

49 The data and a report from a study in respect of the substance, conducted in accordance with

(a) the methodology described in *Test No. 474: Mammalian Erythrocyte Micronucleus Test* of the OECD Guidelines, Section 4, that is current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

50 (1) The data and a report from a study in respect of the substance, conducted in accordance with

(a) the methodology described in *Test No. 475: Mammalian Bone Marrow Chromosomal Aberration Test* of the OECD Guidelines, Section 4, that is current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

(2) Data substantiating that the investigated tissue was exposed to the substance or its metabolites.

51 The data and a report from a study in respect of the substance, conducted in accordance with

(a) the methodology described in *Test No. 476: In Vitro Mammalian Cell Gene Mutation Tests using the Hprt and xprt genes* of the OECD Guidelines, Section 4, that is current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

52 The data and a report from a study in respect of the substance, conducted in accordance with

(a) the methodology described in *Test No. 487: In Vitro Mammalian Cell Micronucleus Test* of the OECD Guidelines, Section 4, that is current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

53 The data and a report from a study in respect of the substance, conducted in accordance with

(a) the methodology described in *Test No. 488: Transgenic Rodent Somatic and Germ Cell Gene Mutation Assays* of the OECD Guidelines, Section 4, that is current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

54 The data and a report from a study in respect of the substance, conducted in accordance with

(a) the methodology described in *Test No. 489: In Vivo Mammalian Alkaline Comet Assay* of the OECD Guidelines, Section 4, that is current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

55 The data and a report from a study in respect of the substance, conducted in accordance with

(a) the methodology described in *Test No. 490: In Vitro Mammalian Cell Gene Mutation Tests Using the Thymidine Kinase Gene* of the OECD Guidelines, Section 4, that is current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

56 (1) The data and a report from a ready biodegradation study in respect of the substance, conducted in accordance with

(a) a methodology that is consistent with the conditions and procedures set out in any of the OECD Guidelines that are relevant to the study and current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

(2) The products of biodegradation, if known.

57 The data and a report from an acute fish, daphnia or algae toxicity study in respect of the substance — with the type of study being selected on the basis of the most sensitive of those species — conducted in accordance with

(a) a methodology that is consistent with the conditions and procedures set out in any of the OECD Guidelines that are relevant to the study and current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

58 The data and a report from an acute fish toxicity study in respect of the substance, conducted in accordance with

(a) a methodology that is consistent with the conditions and procedures set out in any of the OECD Guidelines that are relevant to the study and current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

59 The data and a report from an acute daphnia toxicity study in respect of the substance, conducted in accordance with

(a) a methodology that is consistent with the conditions and procedures set out in any of the OECD Guidelines that are relevant to the study and current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

60 The data and a report from an acute algae toxicity study in respect of the substance, conducted in accordance with

(a) a methodology that is consistent with the conditions and procedures set out in any of the OECD Guidelines that are relevant to the study and current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

61 (1) The data and a report from an oral, dermal or inhalation acute mammalian toxicity study in respect of the substance — with the type of study being selected on the basis of the most significant route of potential human exposure to the substance — conducted in accordance with

(a) a methodology that is consistent with the conditions and procedures set out in any of the OECD Guidelines that are relevant to the study and current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

(2) The following information in respect of the study:

(a) the number of animals tested and the age, sex, species, strain and source of each animal;

(b) the route by which and manner in which the substance is administered and the conditions under which the study is conducted; and

(c) the dose of the substance, the vehicle by means of which the substance is administered and the concentration of the substance in the vehicle.

62 (1) The data and a report from an oral acute mammalian toxicity study in respect of the substance, conducted in accordance with

(a) a methodology that is consistent with the conditions and procedures set out in any of the OECD Guidelines that are relevant to the study and current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

(2) The following information in respect of the study:

(a) the number of animals tested and the age, sex, species, strain and source of each animal;

(b) the manner in which the substance is administered and the conditions under which the study is conducted; and

(c) the dose of the substance, the vehicle by means of which the substance is administered and the concentration of the substance in the vehicle.

63 (1) The data and a report from a dermal acute mammalian toxicity study in respect of the substance, conducted in accordance with

(a) a methodology that is consistent with the conditions and procedures set out in any of the OECD Guidelines that are relevant to the study and current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

(2) The following information in respect of the study:

(a) the number of animals tested and the age, sex, species, strain and source of each animal;

(b) the manner in which the substance is administered and the conditions under which the study is conducted; and

(c) the dose of the substance, the vehicle by means of which the substance is administered and the concentration of the substance in the vehicle.

64 (1) The data and a report from an inhalation acute mammalian toxicity study in respect of the substance, conducted in accordance with

(a) a methodology that is consistent with the conditions and procedures set out in any of the OECD Guidelines that are relevant to the study and current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

(2) The following information in respect of the study:

(a) the number of animals tested and the age, sex, species, strain and source of each animal;

(b) the manner in which the substance is administered and the conditions under which the study is conducted; and

(c) the dose of the substance, the vehicle by means of which the substance is administered and the concentration of the substance in the vehicle.

65 (1) The data and a report from an oral, dermal or inhalation repeated-dose mammalian toxicity study of at least 28 days in respect of the substance — with the type of study being selected on the basis of the most significant route of potential human exposure to the substance — conducted in accordance with

(a) a methodology that is consistent with the conditions and procedures set out in any of the OECD Guidelines that are relevant to the study and current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

(2) The following information in respect of the study:

(a) the number of animals tested and the age, sex, species, strain and source of each animal;

(b) the route by which and manner in which the substance is administered and the conditions under which the study is conducted; and

(c) the dose of the substance, the vehicle by means of which the substance is administered and the concentration of the substance in the vehicle.

66 (1) The data and a report from an oral repeated-dose mammalian toxicity study of at least 28 days in respect of the substance, conducted in accordance with

(a) a methodology that is consistent with the conditions and procedures set out in any of the OECD Guidelines that are relevant to the study and current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

(2) The following information in respect of the study:

(a) the number of animals tested and the age, sex, species, strain and source of each animal;

(b) the manner in which the substance is administered and the conditions under which the study is conducted; and

(c) the dose of the substance, the vehicle by means of which the substance is administered and the concentration of the substance in the vehicle.

67 (1) The data and a report from a dermal repeated-dose mammalian toxicity study of at least 28 days in respect of the substance, conducted in accordance with

(a) a methodology that is consistent with the conditions and procedures set out in any of the OECD Guidelines that are relevant to the study and current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

(2) The following information in respect of the study:

(a) the number of animals tested and the age, sex, species, strain and source of each animal;

(b) the manner in which the substance is administered and the conditions under which the study is conducted; and

(c) the dose of the substance, the vehicle by means of which the substance is administered and the concentration of the substance in the vehicle.

68 (1) The data and a report from an inhalation repeated-dose mammalian toxicity study of at least 28 days in respect of the substance, conducted in accordance with

(a) a methodology that is consistent with the conditions and procedures set out in any of the OECD Guidelines that are relevant to the study and current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

(2) The following information in respect of the study:

(a) the number of animals tested and the age, sex, species, strain and source of each animal;

(b) the manner in which the substance is administered and the conditions under which the study is conducted; and

(c) the dose of the substance, the vehicle by means of which the substance is administered and the concentration of the substance in the vehicle.

69 (1) The data and a report from a skin irritation study in respect of the substance, conducted in accordance with

(a) a methodology that is consistent with the conditions and procedures set out in any of the OECD Guidelines that are relevant to the study and current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

(2) The following information in respect of the study:

(a) the number of animals tested and the age, sex, species, strain and source of each animal;

(b) the manner in which the substance is administered and the conditions under which the study is conducted; and

(c) the dose of the substance, the vehicle by means of which the substance is administered and the concentration of the substance in the vehicle.

70 (1) The data and a report from a skin sensitization study in respect of the substance, conducted in accordance with

(a) a methodology that is consistent with the conditions and procedures set out in any of the OECD Guidelines that are relevant to the study and current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

(2) The following information in respect of the study:

(a) the number of animals tested and the age, sex, species, strain and source of each animal;

(b) the manner in which the substance is administered and the conditions under which the study is conducted; and

(c) the dose of the substance, the vehicle by means of which the substance is administered and the concentration of the substance in the vehicle.

71 The data and a report from an *in vitro* gene mutation study in respect of the substance, with and without metabolic activation, conducted in accordance with

(a) a methodology that is consistent with the conditions and procedures set out in any of the OECD Guidelines that are relevant to the study and current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

72 The data and a report from an *in vitro* mammalian chromosomal aberration study in respect of the substance, with and without metabolic activation, conducted in accordance with

(a) a methodology that is consistent with the conditions and procedures set out in any of the OECD Guidelines that are relevant to the study and current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

73 (1) The data and a report from an *in vivo* mammalian chromosomal aberration study, gene mutation study or other mutagenicity study that permits an assessment of *in vivo* mutagenicity in respect of the substance, conducted in accordance with

(a) a methodology that is consistent with the conditions and procedures set out in any of the OECD Guidelines that are relevant to the study and current at the time the study is conducted; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

(2) The following information in respect of the study:

(a) the number of animals tested and the age, sex, species, strain and source of each animal;

(b) the route by which and manner in which the substance is administered and the conditions under which the study is conducted; and

(c) the dose of the substance, the vehicle by means of which the substance is administered and the concentration of the substance in the vehicle.

(3) Data substantiating that the tissue investigated was exposed to the substance or its metabolites.

74 The following data and a report from a study in respect of the substance, conducted in accordance with a methodology that is consistent with the conditions and procedures set out in any of the OECD Guidelines that are relevant to the study and current at the time the study is conducted:

(a) the melting point of the substance or the temperature at which it decomposes

(i) expressed in degrees Celsius, if the melting point or temperature is − 25°C or greater but not greater than 300°C, or

(ii) expressed as “less than − 25°C” or “greater than 300°C”, as appropriate, in any other case;

(b) the boiling point of the substance or the temperature at which it decomposes

(i) expressed in degrees Celsius, if the boiling point or temperature is − 50°C or greater but not greater than 300°C, or

(ii) expressed as “less than − 50°C” or “greater than 300°C”, as appropriate, in any other case;

(c) the density of the substance; and

(d) the vapour pressure of the substance, if it has a standard boiling point of 0°C or greater.

75 The following data and a report from a study in respect of the substance, conducted in accordance with a methodology that is consistent with the conditions and procedures set out in any of the OECD Guidelines that are relevant to the study and current at the time the study is conducted:

(a) the water solubility of the substance; and

(b) a spectral characterization of the substance using infrared, ultraviolet, mass or nuclear magnetic resonance, as appropriate.

76 The following data and a report from a study in respect of the substance, conducted in accordance with a methodology that is consistent with the conditions and procedures set out in any of the OECD Guidelines that are relevant to the study and current at the time the study is conducted:

(a) the octanol-water partition coefficient of the substance;

(b) adsorption-desorption screening test data; and

(c) the hydrolysis rate of the substance as a function of pH and, if known, the products of the hydrolysis.

77 The following data and a report from a study in respect of the substance, conducted in accordance with a methodology that is consistent with the conditions and procedures set out in any of the OECD Guidelines that are relevant to the study and current at the time the study is conducted:

(a) the number average molecular weight of the substance;

(b) the maximum concentrations, expressed as a percentage, of all residual constituents having molecular weights of less than 500 daltons and of all residual constituents having molecular weights of less than 1 000 daltons; and

(c) the water extractability of the substance measured at

(i) pH 7, in the case of anionic and neutral substances,

(ii) pH 2 and 7, in the case of cationic substances, or

(iii) pH 2, 7 and 9, in the case of amphoteric substances.

78 The following data and a report from a study in respect of the substance, conducted in accordance with a methodology that is consistent with the conditions and procedures set out in any of the OECD Guidelines that are relevant to the study and current at the time the study is conducted:

(a) the primary and secondary particle size distributions of the substance and the necessary analytical data to determine those distributions; and

(b) the agglomeration state and aggregation state, shape, surface area, surface functionalization and surface charge of the substance, and the necessary analytical data to determine those properties.

79 The data and a report from a study in respect of the substance, conducted in accordance with

(a) Report EPS 1/RM/32, *Biological Test Method: Test for Survival and Growth in Sediment Using Larvae of Freshwater Midges (Chironomus tentans or Chironomus riparius)*, published by Environment Canada in December 1997; and

(b) the OECD principles of good laboratory practice that are current at the time the study is conducted.

PART 3

Additional Information

1 All other information or test data in respect of the substance that is in the possession of the person proposing the significant new activity, or to which they may reasonably be expected to have access, and that permits the identification of the adverse effects that the substance may have on the environment and human health and the degree of environmental and public exposure to the substance.

2 The name of every other government department or agency, either outside or within Canada, to which the person proposing the significant new activity has provided information regarding the use of the substance — as well as the department's or agency's file number, if known — and, if any, the outcome of the department's or agency's assessment and the risk management actions that the department or agency has imposed in relation to the substance.

3 Contact information for the person proposing the significant new activity — specifically, their name, civic and postal addresses, telephone number and, if any, fax number and email address — and, if they are not resident in Canada, for the person resident in Canada who is authorized to act on their behalf.

4 A certification that the information provided to the Minister is accurate and complete, dated and signed by the person proposing the significant new activity or, if they are not resident in Canada, by the person resident in Canada who is authorized to act on their behalf.

REGULATORY IMPACT ANALYSIS STATEMENT

(*This statement is not part of the Order*.)

Issues

The Chemicals Management Plan (CMP) is a Government of Canada initiative through which the risks of exposure of people in Canada and the environment to substances [2] are assessed and managed.

As part of the CMP, the Minister of the Environment and the Minister of Health (the ministers) determined that 54 substances on the *Domestic Substances List* [3] (DSL) have properties of concern that could pose a risk to human health or the environment if exposure levels to the substances were to increase from their use in a significant new activity in Canada. To require notification in the event of such an activity, the Minister of the Environment (the Minister) is issuing the *Order 2026-87-20-01 Amending the Domestic Substances List* (the Order) in accordance with subsection 87(3) of the *Canadian Environmental Protection Act, 1999* (the Act) to apply the significant new activity (SNAc) provisions of the Act to the 54 substances listed in Table A in the Annex to this Regulatory Impact Analysis Statement (RIAS).

Also as part of the CMP, the ministers reviewed the SNAc requirements previously applied to 161 substances on the DSL, determining that these requirements do not align with current information on the substances, policies and approaches. As a result, the Minister is issuing the Order in accordance with subsection 87(4.1) of the Act to vary the SNAc requirements applied to the 161 substances listed in Table B in the Annex to this RIAS.

In addition, two structural changes to the DSL are being undertaken to increase efficiency and consistency for orders applying the SNAc provisions of the Act to a substance. Firstly, in accordance with subsection 66(1) of the Act, the Minister is issuing the Order to split Part 2 of the DSL into Division 1 (which sets out substances subject to individualized SNAc requirements, i.e. that are applied to each substance individually) and Division 2 (which sets out substances subject to standardized SNAc requirements, i.e. that are applied to groups of substances). Secondly, in accordance with subsection 66(1) of the Act, the Minister is issuing the Order to create Schedule 1 to the DSL, which sets out the information requirements for the notification of a proposed significant new activity for any substance subject to subsection 81(3) of the Act. By splitting Part 2 of the DSL into two divisions, the Order consequently moves another eight substances to a new location on the DSL (listed in Table C in the Annex to this RIAS), for which the Minister is issuing the Order in accordance with subsection 87(4.1) of the Act to maintain the SNAc requirements previously applied to those eight substances.

Background

Chemicals Management Plan

In 2006, the Government of Canada launched the CMP, a federal program with the objective of reducing the risks posed by certain substances to people in Canada and the environment through sources of exposure, such as food and food products, consumer products, cosmetics, drugs, drinking water and industrial releases. As part of the CMP, the ministers conduct assessments under the authority of the Act to identify existing or potential environmental and human health risks posed by exposure to those substances. The ministers may recommend the development of risk management measures to mitigate these risks under the authority of a

broad suite of federal laws, including the *Canadian Environmental Protection Act, 1999*, the *Canada Consumer Product Safety Act*, the *Food and Drugs Act*, the *Pest Control Products Act*, and the *Fisheries Act*.

SNAc provisions of the Act

A significant new activity is an activity that results in or may result in the entry or release of the substance into the environment in a greater quantity or concentration than before, or in different circumstances than those in which the substance previously entered or was released into the environment. [4] The SNAc provisions of the Act establish a requirement for any person (individual or corporation) considering manufacturing, importing or using a substance for a significant new activity to submit a Significant New Activity Notification (SNAN) to the Minister containing the prescribed information for that substance. Upon receipt of the complete information, the Department of the Environment and the Department of Health (the departments) conduct further assessment of that substance before the activity is undertaken, to determine whether exposure to that substance from that activity could pose a risk to the environment or human health and whether further risk management considerations may be required to mitigate those risks. To access a list of substances subject to the SNAc provisions of the Act as well as their applicable SNAc requirements, please visit the Canada.ca Open Data Portal.

Summary of the screening assessments for the 54 substances listed in Table A in the Annex to this RIAS

In 2009 and 2012 respectively, the departments completed two phases of the CMP's DSL Inventory Update, which identified 1 009 surveyed substances as being in Canadian commerce at a total quantity of less than or equal to 1 000 kg per year. The ministers published the Rapid Screening of Substances from Phase One in March 2014 (covering 140 of those

substances) and the Rapid Screening of Substances identified from Phase Two in August 2016 (covering 869 of those substances) on the Canada.ca (Chemical Substances) website. The assessments concluded that approximately 70% of the assessed substances do not meet the environmental or human health criteria for a toxic substance as set out in paragraphs 64(a), (b), or (c) of the Act. [5] The assessments also determined that 54 of those substances have properties of concern that could pose a risk to the environment or human health if exposure levels to the substances were to increase as a result of their use in a significant new activity in Canada. As a result, the Minister is applying the SNAc provisions of the Act to the 54 substances listed in Table A in the Annex to this RIAS.

Summary of the screening assessments and previous SNAc requirements for the 169 substances listed in Table B and Table C in the Annex to this RIAS

Between 2008 and 2013, the ministers published various screening assessments covering the 169 substances listed in Table B and Table C in the Annex to this statement on the Canada.ca (Chemical Substances) website, under a series of CMP initiatives. The various screening assessments concluded that the 169 substances do not meet the environmental or human health criteria as set out in paragraphs 64(a), (b), or (c) of the Act. The various assessments also determined that the 169 substances have properties of concern that could pose a risk to the environment or human health if exposure levels to the substances were to increase as a result of their use in a significant new activity in Canada. As a result, the Minister applied the SNAc provisions of the Act to the 169 substances through a variety of ministerial orders. The screening assessments and associated orders are summarized in Table 1.

Table 1: Screening assessments and previous SNAc requirements covering the 169 substances

CMP initiative name and link to screening assessments covering the 169 substances	*Canada Gazette*, Part II, publication date and link to orders covering the 169 substances (applying the SNAc provisions of the Act)	Number of substances assessed that are listed in Table B in the Annex to this RIAS	Number of substances assessed that are listed in Table C in the Annex to this RIAS
Challenge Batch 2	May 27, 2009 (PDF, 801KB)	2	0
Challenge Batch 3	March 18, 2009 (PDF, 1.4MB)	2	0
Challenge Batch 4	August 19, 2009 (PDF, 2.3MB)	4	0
Challenge Batch 5	November 10, 2010 (PDF, 2.3MB)	1	0
Challenge Batch 6	November 10, 2010 (PDF, 1.3MB)	2	0
Challenge Batch 7	March 31, 2010 (PDF, 1.3MB)	1	0
Challenge Batch 8	August 18, 2010 (PDF, 1.6MB)	2	0
Challenge Batch 9	September 29, 2010 (PDF, 610KB)	5	0

a As a consequence of the structural changes that the Order makes to the DSL, the location of these eight substances on the DSL must also change. As a result, under the authority of subsection 87(4.1) of the Act, the Minister is maintaining the SNAc requirements previously applied to the eight substances listed in Table C in the Annex to this RIAS.

Challenge Batch 11	September 14, 2011 (PDF, 1.7MB)	4	0
Challenge Batch 12	July 3, 2013 (PDF, 2MB)	2	0
High Hazard Potential	May 22, 2013 (PDF, 1.5MB)	51	0
Persistent, Bioaccumulative and inherently Toxic (PBiT)	June 25, 2008 (PDF, 5.9MB)	85	8 [a]

[a] As a consequence of the structural changes that the Order makes to the DSL, the location of these eight substances on the DSL must also change. As a result, under the authority of subsection 87(4.1) of the Act, the Minister is maintaining the SNAc requirements previously applied to the eight substances listed in Table C in the Annex to this RIAS.

Review of SNAc orders and notices

Since the publication of the first SNAc notice in 2001, policies and practices have evolved, particularly with respect to the nature and scope of SNAc orders and notices, as well as the wording used to define a significant new activity. As part of the Significant New Activity orders and notices of the Chemicals Management Plan initiative, a review of all SNAc orders and notices published prior to 2014 is being undertaken to ensure that current SNAc requirements are in step with current information on those substances, policies and approaches. Following the review process, there may be no changes needed for certain SNAc orders and notices, while, for others, rescissions or amendments may be warranted. Under this initiative,

any resulting changes to SNAc requirements are expected to provide greater clarity of scope and improved ease of compliance, while protecting people in Canada and their environment.

Review of the SNAc requirements previously applied to the 161 substances listed in Table B in the Annex to this RIAS

Between 2016 and 2022, the departments completed a review of the SNAc requirements previously applied to 161 substances. The review considered any new or increased use of the substances in consumer products that should require notification to the Minister. The review also identified previous SNAc requirements that did not reflect current policies and approaches (e.g. including explicit definitions for exclusions, removing toxicity testing requirements that are no longer necessary) and identified that the selected threshold for triggering the submission of a SNAN (i.e. at least 100 kg per calendar year) was unnecessarily low for certain substances. The review concluded that the 161 substances continue to not meet the environmental and human health criteria for a toxic substance as set out in section 64 of the Act, and that the substances continue to have properties of concern that could pose a risk to the environment or human health if exposure levels to the substances were to increase as a result of their use in a significant new activity in Canada. While notification to the Minister for significant new activities involving these substances should continue to be required, the SNAc requirements previously applied to 161 substances do not align with current information on the substances, policies and approaches. Thus, under the authority of subsection 87(4.1) of the Act, the Minister is varying the SNAc requirements for the 161 substances listed in Table B in the Annex to this RIAS to achieve alignment.

Domestic Substances List

The DSL provides an inventory of substances in the Canadian marketplace. It was originally published in the *Canada Gazette*, Part II, in 1994, and its structure was amended in 2001 (SOR/2001-214 (PDF, 1.2MB)).

As established by SOR/2001-214, the DSL includes eight parts, defined as follows:

Part 1

Sets out chemicals and polymers, except those referred to in Part 2, 3 or 4 that are identified by their Chemical Abstracts Service (CAS) Registry Numbers [6] or their Substance Identity Numbers assigned by the Department of the Environment and the names of the substances.

Part 2

Sets out chemicals and polymers subject to SNAc requirements that are identified by their CAS Registry Numbers.

Part 3

Sets out chemicals and polymers, except those referred to in Part 4, that are identified by their masked names [7] and their Confidential Substance Identity Numbers (also referred to as Confidential Accession Numbers [CANs]) assigned by the Department of the Environment.

Part 4

Sets out chemicals and polymers subject to SNAc requirements that are identified by their masked names and their CANs.

Part 5

Sets out inanimate biotechnology products and living organisms, except those referred to in Part 6, 7 or 8, that are identified by their American Type Culture Collection (ATCC) numbers, International Union of Biochemistry and Molecular Biology (IUBMB) numbers or specific substance names.

Part 6

Sets out inanimate biotechnology products and living organisms subject to SNAc requirements that are identified by their ATCC numbers, IUBMB

numbers or specific substance names.

Part 7

Sets out inanimate biotechnology products and living organisms, except those referred to in Part 8, that are identified by their masked names and their CANs.

Part 8

Sets out inanimate biotechnology products and living organisms subject to SNAc requirements that are identified by their masked names and their CANs.

Splitting Part 2 of the DSL into Division 1 and Division 2, and creating Schedule 1 to the DSL

Many substances assessed under the CMP (including the majority of the 223 substances subject to this Order) are assessed and reviewed in groups based on similar physical, chemical or toxicological properties, and therefore, similar assessment conclusions tend to apply across various substances within those groups. Similarly, should the substances that were assessed as groups become subject to requirements under the SNAc provisions of the Act, the same SNAc definition and information requirements can apply across multiple substances. Given the previous structure of the DSL (as described above), administrative efficiencies from these grouped similarities cannot be realized. In order to enable the efficient consolidation of substances subject to the same SNAc definition and information requirements on the DSL, the Minister is splitting Part 2 of the DSL into Division 1 and Division 2. Division 1 sets out chemicals and polymers identified by CAS Registry Numbers and subject to the SNAc provisions of the Act when those provisions are applied to each substance individually. Division 2 sets out chemicals and polymers identified by their CAS Registry Numbers and subject to the SNAc provisions of the Act when those provisions are applied in respect of groups of substances.

To facilitate compliance with SNAc requirements as well as enable further administrative efficiencies, the Minister is also creating Schedule 1 to the DSL, titled “Information Concerning Significant New Activities in Respect of Which a Substance is Subject to Subsection 81(3) of the Act.” Schedule 1 sets out information that can be referred to by subsequent orders applying the SNAc provisions of the Act to a substance. Accordingly, the creation of Schedule 1 will increase consistency between orders and streamline their publications.

Objective

The objectives of *Order 2026-87-20-01 Amending the Domestic Substances List* (the Order) are

- to apply the SNAc provisions of the Act to the 54 substances listed in Table A in the Annex to this RIAS, contributing to the protection of the environment and human health by reducing the risks associated with increased exposure of people in Canada and the environment to these substances in the event of their use in a significant new activity in Canada;
- to vary the SNAc requirements previously applied to the 161 substances listed in Table B in the Annex to this RIAS and maintain the SNAc requirements previously applied to the 8 substances listed in Table C in the Annex to this RIAS, contributing to greater alignment of SNAc requirements with current information, policies and approaches, while maintaining the protection of people in Canada and their environment; and
- to split Part 2 of the DSL into Division 1 (for individual substances) and Division 2 (for groups of substances) and to create Schedule 1 to the DSL (for information requirements for the notification of a proposed

significant new activity), contributing to greater efficiency and improved consistency for orders applying the SNAc provisions of the Act to a substance.

Description

The Order is made pursuant to subsections 66(1), 87(3) and 87(4.1) of the Act. The Order applies the SNAc provisions of the Act to the 54 substances listed in Table A in the Annex to this RIAS, varies the SNAc requirements previously applied to the 161 substances listed in Table B in the Annex to this RIAS, maintains the SNAc requirements previously applied to the 8 substances listed in Table C in the Annex to this RIAS, and makes structural changes to the DSL to split Part 2 of the DSL into Division 1 and Division 2, and to create Schedule 1 to the DSL. In applying the SNAc provisions of the Act to 54 substances and splitting Part 2 of the DSL into two divisions, the Order consequently changes the DSL location of the 223 substances listed in Table A, Table B and Table C in the Annex to this RIAS.

Applicability and SNAc requirements

The SNAc provisions of the Act now apply to the 54 substances listed in Table A in the Annex to this RIAS, and continue to apply to the 169 substances listed in Table B and Table C in the Annex to this RIAS. Accordingly, it is mandatory to meet the requirements of subsection 81(3) of the Act before manufacturing, importing or using these substances for a significant new activity as defined in the Order. For details on the significant new activities associated with the 223 substances (such as reporting thresholds and exemptions), please refer to the Order. Any person who proposes to engage in a significant new activity in relation to the 223 substances is required to submit a SNAN to the Minister containing all the information prescribed in the Order and submitted in the prescribed

period before the day on which the significant new activity begins. [8] For details on the information required in a SNAN for the 223 substances, please refer to the Order.

For clarity, the Order does not impose any regulatory requirements on existing activities involving the 223 substances in Canada, which have been determined to present no or limited risk, or to be adequately managed.

Structural changes to the DSL

Part 2 of the DSL ("Chemicals and polymers to which subsection 81(3) of the Act applies and that are identified by Chemical Abstracts Service Registry Numbers") is split into the following two divisions:

- Division 1 "Individual Substances"; and
- Division 2 "Groups of Substances."

Schedule 1 to the DSL ("Information Concerning Significant New Activities in Respect of Which a Substance is Subject to Subsection 81(3) of the Act"), is created as an annex to the DSL. Schedule 1 consists of the following three parts:

- Part 1 "Information in Respect of Significant New Activities and Substances";
- Part 2 "Data and Reports from Studies in Respect of Substances"; and
- Part 3 "Additional Information."

Relocating 223 substances on the DSL

The 54 substances listed in Table A in the Annex to this RIAS are deleted from Part 1, of which:

- 39 are added, along with their mutual SNAc requirements, to Part 2, Division 2 (Group 1);

- 12 are added, along with their mutual SNAc requirements, to Part 2, Division 2 (Group 2); and
- 3 are added, along with their mutual SNAc requirements, to Part 2, Division 2 (Group 3).

The 161 substances listed in Table B in the Annex to this RIAS, along with their previous SNAc requirements, are deleted from Part 2, of which

- 2 are added, along with their individual SNAc requirements, to Part 2, Division 1;
- 27 are added, along with their mutual SNAc requirements, to Part 2, Division 2 (Group 2);
- 16 are added, along with their mutual SNAc requirements, to Part 2, Division 2 (Group 3);
- 73 are added, along with their mutual SNAc requirements, to Part 2, Division 2 (Group 4);
- 33 are added, along with their mutual SNAc requirements, to Part 2, Division 2 (Group 5);
- 5 are added, along with their mutual SNAc requirements, to Part 2, Division 2 (Group 6); and
- 5 are added, along with their mutual SNAc requirements, to Part 2, Division 2 (Group 7).

The 8 substances listed in Table C in the Annex to this RIAS, along with their previous SNAc requirements, are deleted from Part 2, and added, along with their mutual SNAc requirements, to Part 2, Division 2 (Group 8).

Regulatory development

Consultation

Many of the substances covered by the Order were subject to calls for public comment under different initiatives pursuant to the CMP.

To begin, on December 3, 2016, the Minister published a Notice of Intent (NOI) to apply the SNAc provisions of the Act to 54 substances (listed in Table A in the Annex to this RIAS) in the *Canada Gazette*, Part I, for a 60-day public comment period. The Department of the Environment (the Department) received two comments from industry stakeholders during this period, neither of which opposed the application of the SNAc provisions to the substances. Accordingly, the definition of significant new activities and the information requirements applied to the 54 substances are the same in the Order as those proposed in the NOI.

Next, on January 14, 2017, the Minister published a NOI to vary the SNAc requirements for 26 substances (one of which is listed in Table B in the Annex to this RIAS) in the *Canada Gazette*, Part I, for a 60-day public comment period. While the Department did not receive any comments specific to this substance, it received an overarching comment from an industry stakeholder that applies to the substance. Specifically, the commentor did not support the reduction of the reporting threshold from 100 kg to 10 kg in a calendar year for significant new activities involving a consumer product containing the substance at a concentration equal to or greater than 0.1% by weight. Government officials responded that 10 kg is the threshold applied to activities involving consumer products and is appropriate to address human health concerns. Accordingly, the variance to the reporting threshold for the substance is the same in the Order as that proposed in the NOI.

After that, on July 27, 2019, the Minister published a NOI to vary the SNAc requirements for 110 substances (105 of which are listed in Table B in the Annex to this RIAS) in the *Canada Gazette*, Part I, for a 60-day public

comment period. The Department received one comment from a private citizen during this period, pertaining to the management of occupational hazards of the substances. While the comment was considered in the development of the Order, the Department assessed the comment as being beyond the scope of the Act, and, therefore, the variance to the SNAc requirements applied to the 105 substances is the same in the Order as that proposed in the NOI.

Finally, on February 5, 2022, the Minister published a NOI to vary the SNAc requirements for 10 substances (listed in Table B in the Annex to this RIAS) and a NOI to vary the SNAc requirements for 46 substances (PDF, 1.4MB) [45 of which are listed in Table B in the Annex to this RIAS] in the *Canada Gazette*, Part I, for a 60-day public comment period. The Department received no comments during this period.

The Act does not prescribe a public comment period for amendments to the DSL. Given the administrative nature of this amendment, the Department deemed public consultation for the splitting of Part 2 of the DSL into Division 1 and Division 2 and the creation of Schedule 1 to the DSL to be unnecessary.

The departments also informed the provincial and territorial governments about the Order through the Canadian Environmental Protection Act National Advisory Committee via a letter and provided them with an opportunity to comment. No comments were received from the Committee.

Indigenous engagement, consultation and modern treaty obligations

Orders amending the DSL to apply the SNAc provisions of the Act to certain substances, to vary or maintain the SNAc requirements previously applied to certain substances, or to change the structure of the DSL do not result in

any impact on modern treaty rights or obligations, as they do not impose regulatory requirements (see “Applicability and SNAc requirements” section) that could result in incremental impacts (see “Benefits and costs” section). As such, specific engagement and consultations with Indigenous Peoples were not undertaken.

Instrument choice

For the 54 substances listed in Table A in the Annex to this RIAS, the decision to use the SNAc provisions of the Act is risk-based. The SNAc provisions are considered for use where there is reasonable suspicion that certain new activities with respect to a substance may result in new or increased risks to the environment or human health. That suspicion could be based on factors such as the specific properties of that substance, the function of that substance and the presence of that substance in markets in other jurisdictions. [9] The assessment informed the determination that applying the SNAc provisions of the Act to the 54 substances is the most appropriate instrument to mitigate the risks of increased exposure of people in Canada and the environment to the substances in the event of use in a significant new activity in Canada.

For the 169 substances listed in Table B and Table C in the Annex to this RIAS, the Order is the only available instrument under the Act to vary or maintain the requirements applied to the 169 substances under the SNAc provisions of the Act. Likewise, the Order is the only available instrument under the Act to change the structure of the DSL.

Regulatory analysis

Benefits and costs

For the 54 substances listed in Table A in the Annex to this RIAS, orders amending the DSL to apply the SNAc provisions of the Act to certain substances do not result in incremental impacts (benefits and costs). The SNAc provisions aid in the protection of the environment and human health through their contribution to the main objective of the CMP. These orders usually do not apply to current activities identified at the time of the analysis involving those substances, as they are not considered to pose an environmental or human health risk, or their risk is considered to be adequately managed. These orders apply to the potential use of those substances in a significant new activity that could result in a new or increased exposure to those substances. Should a person (individual or corporation) choose to engage in a significant new activity involving a substance subject to the SNAc provisions of the Act, they would be required to comply with all the regulations in place associated with that activity and that substance, including the requirement to submit a SNAN to the Minister. Therefore, the costs associated with the submission of a SNAN are not considered incremental to the SNAc provisions for a substance, but rather costs of conducting business and/or complying with federal laws and regulations in Canada.

For the 161 substances listed in Table B in the Annex to this RIAS, orders varying the SNAc requirements previously applied to a substance may result in certain activities for which a SNAN would not have been submitted to the Minister to now be subject to the SNAc provisions of the Act or vice versa. In such a scenario, the administrative burden associated with the submission of a SNAN may increase or decrease relative to the baseline scenario. However, it is unknown whether any SNANs would have been submitted to the Minister in the baseline scenario, and whether any SNANs will now be submitted to the Minister, given the varied SNAc requirements. Thus, the extent of any potential increase or decrease in administrative

burden is unknown. The benefit of orders varying the SNAc requirements previously applied to a substance is enhanced alignment of requirements with current information, policies and approaches, while maintaining the protection of people in Canada and their environment. For the eight substances listed in Table C in the Annex to this RIAS, orders maintaining the SNAc requirements previously applied to a substance have no impact relative to the baseline scenario.

The structural changes to the DSL do not result in any costs to industry or government. The benefit of splitting Part 2 of the DSL into two divisions and creating Schedule 1 to the DSL is improved efficiency for listing substances assessed as groups and greater consistency for orders applying the SNAc provisions of the Act to a substance.

Small business lens

For the 54 substances listed in Table A in the Annex to this RIAS, since orders amending the DSL to apply the SNAc provisions of the Act to certain substances do not result in incremental impacts (benefits and costs), they do not have impacts on small businesses and the small business lens was not applied. [10] For the 161 substances listed in Table B in the Annex to this RIAS, since orders varying the SNAc requirements previously applied to a substance usually do not apply to current activities involving those substances and the rate of use of those substances in a significant new activity relative to the baseline is unknown, these orders are not expected to have impacts on small businesses. For the 8 substances in Table C in the Annex to this RIAS, since orders maintaining the SNAc requirements previously applied to a substance have no impact relative to the baseline scenario, they have no impact on small businesses. Since the structural changes to the DSL do not result in any costs to industry, they also have no impact on small businesses.

One-for-one rule

For the 54 substances listed in Table A in the Annex to this RIAS, since orders amending the DSL to apply the SNAc provisions of the Act to certain substances do not result in incremental impacts (benefits and costs), they do not impose new administrative burden on business and the one-for-one rule does not apply. [11] For the 161 substances listed in Table B in the Annex to this RIAS, since orders varying the SNAc requirements previously applied to a substance usually do not apply to current activities involving those substances and the rate of use of those substances in a significant new activity relative to the baseline is unknown, these orders are not expected to have impacts on businesses that would need to be addressed under the rule. For the eight substances in Table C in the Annex to this RIAS, since orders maintaining the SNAc requirements previously applied to a substance have no impact relative to the baseline scenario, they have no impacts that would need to be addressed under the rule. Since the structural changes to the DSL do not result in any costs to industry, they also do not have impacts that would need to be addressed under the rule.

Regulatory cooperation and alignment

Canada cooperates with other international organizations and regulatory agencies for the management of chemicals (e.g. the United States Environmental Protection Agency, the European Chemicals Agency, and the Organisation for Economic Cooperation and Development) and is party to several international multilateral environmental agreements in the area of chemicals and waste. [12] The CMP is administered in cooperation and alignment with these agreements.

International obligations

The Order is not subject to any obligations under Canada's international trade agreements.

Effects on the environment

In accordance with the *Cabinet Directive on Strategic Environmental and Economic Assessment* (SEEA), a SEEA is required for proposals that are expected to have important effects (positive or negative, direct or indirect) on the environment and economy. Since orders amending the DSL to apply the SNAc provisions of the Act to certain substances do not result in incremental impacts (benefits and costs), a SEEA is not required. Similarly, a SEEA is not required for orders varying or maintaining the SNAc requirements previously applied to a substance, nor for orders changing the structure of the DSL.

Right to a healthy environment

In the administration of the Act, the Government of Canada has a duty to protect the right to a healthy environment as provided for under the Act, subject to reasonable limits. An implementation framework published in accordance with subsection 5.1(1) of the Act sets out considerations to protect this right and uphold the principles described in the framework.

Work to inform this Order began before the implementation framework was published on July 19, 2025. Recognizing that decisions made under the Act are informed by analyses and consultations that are often the result of years of work, a transition period is in place to allow the departments to support continued protection of the environment and human health. The objective of the transition period is to continue to advance timely decisions and actions under the Act, while consideration of the right to a healthy environment and relevant principles are being fully integrated into the administration of the Act. This Order is proceeding under the transition

period referenced in the framework and will support protection of human health and the environment from substances of potential concern by allowing further risk assessment of these substances if they are notified for use in a significant new activity in Canada.

Although the implementation framework was not available to be applied from the beginning of the work undertaken to inform this Order, elements of the framework were considered. For example, the best available scientific information was relied upon in making the decisions outlined in this Order. Efforts were made to allow members of the public, including those most likely to be impacted by the decision, to participate in the decision-making process by offering public comment periods for every substance listed in Table A and Table B in the Annex of this RIAS (see "Consultation" section). Moreover, applying the SNAc provisions of the Act to 54 substances and varying the SNAc requirements applied to 161 substances on the DSL to ensure they are in step with current information on those substances, policies and approaches allows for improved access to up-to-date information about each of the substances, and the two structural changes to the DSL further align with the framework, as they increase access to information on the substances in Part 2 of the DSL.

Gender-based analysis plus

For the 54 substances listed in Table A in the Annex to this RIAS, since orders amending the DSL to apply the SNAc provisions of the Act to certain substances do not result in incremental impacts (benefits and costs), the gender-based analysis plus does not apply. [13] For the 161 substances listed in Table B in the Annex to this RIAS, since orders varying the SNAc requirements previously applied to a substance usually do not apply to current activities involving those substances and the rate of use of those substances in a significant new activity relative to the baseline is unknown,

these orders are not expected to have impacts that would need to be addressed under a gender-based analysis plus. For the eight substances in Table C in the Annex to this RIAS, since orders maintaining the SNAc requirements previously applied to a substance have no impact relative to the baseline scenario, they have no impacts that would need to be addressed under a gender-based analysis plus. Since the structural changes to the DSL do not result in costs and the benefits are administrative in nature, they also do not have impacts that would need to be addressed under a gender-based analysis plus.

Implementation, compliance and enforcement, and service standards

Implementation

Orders amending the DSL come into force on the day that they are registered. Compliance promotion activities conducted as part of the implementation of those orders will include developing and distributing promotional material, responding to inquiries from stakeholders and undertaking activities to raise industry stakeholders' awareness of the requirements in those orders in the event that a substance subject to the SNAc provisions of the Act is used in a significant new activity in Canada.

Compliance and enforcement

When assessing whether the use of a substance subject to the SNAc provisions of the Act may be considered a significant new activity, a person is expected to make use of information in their possession, or to which they may reasonably be expected to have access. This means information in any of the notifier's offices worldwide, or other locations where the notifier can reasonably have access to the information. For example, manufacturers are

expected to have access to their formulations, while importers or users of a substance, mixture, or product are expected to have access to import records, usage information and the relevant Safety Data Sheet. [14]

Where a person involved in activities with a substance obtains information that reasonably supports the conclusion that that substance is toxic or is capable of becoming toxic, the person is obligated, under section 70 of the Act, to provide that information to the Minister without delay.

Under subsection 87.1(1) of the Act, any person who transfers the physical possession or control of a substance subject to the SNAc provisions of the Act to another person shall notify that person of their obligation to comply with those provisions, including the obligation to notify the Minister of any significant new activity and to provide all the required prescribed information specified in the SNAc order. A person is not required to be notified under subsection 87.1(1) if they are within a class of person that is specified in the order for the purpose of subsection 87.1(2). For details on the applicable classes of persons for each of the 223 substances, please refer to the Order.

In cases where a person receives physical possession or control of a substance subject to the SNAc provisions of the Act from another person, they may not be required to submit a SNAN, under certain conditions, if their activities were covered by an original SNAN submitted by the supplier on behalf of its clients.

A pre-notification consultation (PDF) (PNC) is available for notifiers who wish to consult during the planning or preparation of a SNAN to discuss any questions or concerns they have about the prescribed information and test plans. Where a person has questions concerning their obligations to

comply with an order, believes they may be out of compliance, or would like to request a PNC, they are encouraged to contact the Substances Management Information Line. [15]

Orders amending the DSL to apply the SNAc provisions of the Act to certain substances are enforced in accordance with the *Compliance and Enforcement Policy for the Canadian Environmental Protection Act, 1999*. In instances of non-compliance, deciding which enforcement measure to take will consider factors such as the nature of the alleged violation, effectiveness in achieving compliance with the Act and its regulations and consistency in the application of enforcement measures. Suspected violations under the Act can be reported to the Enforcement Branch by email at enviroinfo@ec.gc.ca.

Service standards

In the event that a SNAN is submitted to the Minister in relation to any of the 223 substances in Table A, Table B or Table C in the Annex to this RIAS, the information provided will be assessed within the prescribed timelines set out in the Order.

Contacts

Marc Demers
Acting Director
Regulatory Operations, Policy and Emerging Sciences Division
Department of the Environment
Gatineau, Quebec
K1A 0H3
Substances Management Information Line:

1-800-567-1999 (toll-free in Canada) or
819-938-3232 (outside of Canada)
Email: substances@ec.gc.ca

Andrew Beck
Director
Risk Management Bureau
Department of Health
Ottawa, Ontario
K1A 0K9
Telephone: 613-266-3591
Email: andrew.beck@hc-sc.gc.ca

ANNEX

Table A: The 54 substances with SNAc provisions being applied

DSL location	Substances by CAS Registry Number
Part 2 Division 2, Section 1 (Group 1)	51-48-9, 101-65-5, 123-69-3, 302-79-4, 507-28-8, 751-94-0, 1796-92-5, 2944-30-1, 3910-35-8, 4091-99-0, 5284-79-7, 7717-62-6, 7774-29-0, 10595-60-5, 14239-68-0, 19014-53-0, 41284-31-5, 47742-71-2, 49757-42-8, 52236-80-3, 52434-90-9, 61790-11-2, 61790-54-3, 63148-76-5, 63568-35-4, 68083-40-9, 68201-19-4, 68228-09-1, 68334-11-2, 68603-64-5, 68648-44-2, 69304-37-6, 71487-01-9, 73003-83-5, 106068-87-5, 107667-02-7, 114792-68-6, 132373-76-3, 143106-84-7
Part 2 Division 2, Section 2 (Group 2)	87-62-7, 98-95-3, 135-88-6, 140-41-0, 1314-20-1, 4454-16-4, 4995-91-9, 6804-07-5, 7580-31-6, 14816-18-3, 50471-44-8, 68610-24-2

Part 2 Division 2, Section 3 (Group 3)	150-68-5, 18015-76-4, 19900-65-3

Table B: The 161 substances with SNAc requirements being varied

DSL location	Substances by CAS Registry Number
Part 2 Division 1	122-60-1, 10034-93-2
Part 2 Division 2, Section 2 (Group 2)	55-18-5, 60-35-5, 62-50-0, 62-55-5, 66-27-3, 79-16-3, 96-09-3, 96-18-4, 100-63-0, 106-87-6, 115-28-6, 116-14-3, 117-82-8, 123-39-7, 135-20-6, 141-90-2, 331-39-5, 593-60-2, 606-20-2, 1694-09-3, 3296-90-0, 10046-00-1, 13463-39-3, 13840-56-7, 26447-14-3, 39156-41-7, 64742-66-1
Part 2 Division 2, Section 3 (Group 3)	59-88-1, 75-25-2, 76-01-7, 78-88-6, 79-00-5, 94-58-6, 107-05-1, 110-88-3, 123-73-9, 136-35-6, 591-78-6, 615-28-1, 823-40-5, 4170-30-3, 25376-45-8, 103122-66-3
Part 2 Division 2, Section 4 (Group 4)	58-38-8, 76-60-8, 77-52-1, 93-46-9, 116-66-5, 475-71-8, 603-33-8, 603-48-5, 608-71-9, 944-61-6, 1000-05-1, 1176-74-5, 1325-85-5, 1325-86-6, 1326-05-2, 1326-49-4, 2379-75-1, 2538-84-3, 2746-81-8, 3271-22-5, 4395-65-7, 6257-39-2, 6371-23-9, 6373-31-5, 6408-50-0, 6409-68-3, 6417-38-5, 14295-43-3, 15958-61-9, 16834-13-2, 19163-98-5, 25857-05-0, 28118-10-7, 38465-55-3, 40615-36-9, 42479-88-9, 52671-38-2, 53184-75-1, 54079-60-6, 54243-60-6, 56307-70-1, 58019-27-5, 58161-93-6, 59583-77-6, 63281-10-7, 63467-19-6, 64086-95-9, 64086-96-0, 64111-81-5, 68910-11-2, 69898-66-4, 69898-67-5, 70161-19-2, 70776-86-2, 72102-56-8, 72102-64-8, 72318-87-7, 72749-91-8, 75908-83-7, 83006-67-1, 83721-47-5, 83721-48-6, 85186-47-6, 86551-61-3, 90268-98-7, 91696-90-1, 93384-84-0, 94248-26-7, 104376-69-4, 108004-27-9, 113163-36-3, 117310-64-2, 223777-68-2

Part 2 Division 2, Section 5 (Group 5)	87-10-5, 96-66-2, 132-61-6, 133-49-3, 145-39-1, 440-17-5, 626-39-1, 1154-59-2, 2062-78-4, 3687-67-0, 3767-68-8, 23077-61-4, 24169-02-6, 27341-33-9, 36294-24-3, 52591-25-0, 60352-98-9, 63467-15-2, 64325-78-6, 67219-55-0, 68227-79-2, 68938-51-2, 69695-75-6, 72812-39-6, 72828-93-4, 73398-86-4, 73398-87-5, 83968-86-9, 85702-64-3, 101200-53-7, 103331-97-1, 103331-98-2, 125328-28-1
Part 2 Division 2, Section 6 (Group 6)	79-07-2, 131-52-2, 15545-48-9, 24602-86-6, 55290-64-7
Part 2 Division 2, Section 7 (Group 7)	101-61-1, 131-18-0, 492-80-8, 569-61-9, 25321-14-6

Table C: The eight substances with SNAc requirements being maintained

DSL location	Substances by CAS Registry Number
Part 2 Division 2, Section 8 (Group 8)	3701-40-4, 6368-72-5, 6420-06-0, 12789-03-6, 68400-36-2, 68512-30-1, 70210-08-1, 128683-35-2

Footnotes

a S.C. 2023, c. 12, s. 13(1)

b S.C. 2023, c. 12, s. 26

c S.C. 1999, c. 33

1 SOR/94-311

2 Under the *Canadian Environmental Protection Act, 1999* (the Act), these substances include chemicals, polymers, biochemicals, biopolymers, nanomaterials, substances of unknown or variable composition, complex reaction products or biological materials (UVCB), and animate products of biotechnology (living organisms). For more information on the definition of a substance, see subsection 3(1) of the Act.

3 The DSL is an inventory of substances manufactured in or imported into Canada on a commercial scale and can be accessed through the Substances Search web page.

4 For more information, please refer to section 80 and section 104 of the Act.

5 For more information, please refer to section 64 of the Act.

6 The Chemical Abstracts Service Registry Number is the property of the American Chemical Society and any use or redistribution, except as required in supporting regulatory requirements and/or for reports to the Government of Canada when the information and the reports are required by law or administrative policy, is not permitted without the prior, written permission of the American Chemical Society.

7 Masked names are regulated under the *Masked Name Regulations* and are created to protect confidential business information.

8 For guidance on preparing an SNAN, please see section 1.3 and section 4 of the *Guidance document for the New* Substances Notification Regulations (Chemicals and Polymers).

9 For more information on SNAc instrument choice, please consult the Policy on the Use of Significant New Activity Provisions of the *Canadian Environmental Protection Act, 1999*.

10 The assessment of the small business lens has the objective of reducing regulatory costs on small businesses without compromising the health, safety, security and environment of people in Canada.

11 The one-for-one rule requires that, when a new or amended regulation increases the administrative burden cost on business, regulators are required to offset — from their existing regulations — an equal amount on business.

12 For more information on the agreements, please see the Compendium of Canada's engagement in international environmental agreements and instruments. Of particular interest are the Basel Convention on the Control of Transboundary Movements of Hazardous Wastes and Their Disposal, the Rotterdam Convention on the Prior Informed Consent Procedure for Certain Hazardous Chemicals and Pesticides in International Trade, the Stockholm Convention on Persistent Organic Pollutants, and the Minamata Convention on Mercury.

13 A gender-based analysis plus is an analytical process that provides a rigorous method for the assessment of systemic inequalities, as well as a means to assess how diverse groups of women, men, and gender diverse people may experience the incremental impact of policies, programs and initiatives.

14 Although a Safety Data Sheet (SDS) is an important source of information on the composition of a purchased product, it should be noted that the goal of the SDS is to protect the health of workers in the workplace from specific hazards of chemical products and may not include all the information on these hazards. Therefore, an SDS may not list all product ingredients or substances that may be subject to an order. Any person (individual or corporation) requiring additional information on product composition is encouraged to contact their supplier.

15 The Substances Management Information Line can be contacted at substances@ec.gc.ca (email), 1-800-567-1999 (toll-free in Canada), and 819-938-3232 (outside of Canada).